Download Role for cellular CO2 sensor identified Director`s Message

Centre of Excellence hosts
international workshop
dtimpeall. Is maith an rud e gur féidir plé
Rinneamar cur sios agus plé ar gnáth
May 2010.qxd:Layout
1 copy development
Irish
biopharmaceutical
Rinneadh
agallamh
ar 07/05/2010
ceathrar againn 13:12
Pharma
recently
ócompany,
InstitúidSigmoid
Mhic Con
Mhí do
chlár scooped
nua
the overall Innovation of the Year award at
ar
RTE Raidio na Gaeltachta le deanaí.
the inaugural Irish Times All-Island
As a Europeanchlár
Centre ofseo
Excellence,
the
Rachaidh
darbh ainm
Innovationan
Awards. nua
The life-science
SME,
Department
of Rheumatology
ingraduate,
St Vincent’s
‘Ar
StraebysaUCD
tSaotharlann’
i ngleic
leis an
founded
pharmacology
Dr
Ivan
Coulter,
hasan
actively
collaborated
University
Hospital
was chosen
to Labhair
hostwith
an
eolaíocht
agus
timpeallacht.
Conway
Fellow,
Professor
Cormac
Sean
MacFhearraigh,
Sinead
Nic
An
international
two-day
workshop
onTaylor
March
since being granted a Science Foundation
Ultaigh,
Tiarnán
Ó
Máille
agus
mé
féin
26th
&
27th
2010.
Sponsored
by
Roche
Ireland industry research partnership
award
faoin
taighde
éagsúil atá
ar bun againn.
Pharma,
the Participate
workshop
gave
in
2004.
Labhraíomar
neart
réimsí
taighde
twenty
from
centres
in ó
The
Irishrheumatologists
Timesfaoi
award
recognises
the stellar
fiobrois
scámhoige
Alzheimer.
innovative
performance
ofgalar
Sigmoid
Pharma
Europe and
Australiago
the
opportunity
to in
their application of research and development.
witness the care of patients with rheumatoid
The company has developed two new drug
arthritis (RA) LEDDS™
at St Vincent’s.
technologies,
and SmPill™, which not
only enhance the solubility and permeability of
the drug but can deliver it to targeted locations
in the gastrointestinal tract, including the
colon.
Irish biopharmaceutical development
Pagein 3
results
both academic outputs and the
application
research
toward
lá agus naofrudaí
a bhíonn
arclinical
siúl saproduct
development with indigenous companies.”
tsaotharlann anseo san institúid don
The Participate
focused
ongoDr
Commenting
on programme
theMhiníomar
Taylor collaboration,
lucht
éisteachta.
dóibh
Coulter
said,
“The
collaboration
with
the
advanced
treatment
regimens
for
RAeolas
in Taylor
thea
ndéanamar
taighde
áirithe chun
laboratory
clearly practical
demonstrates
theofpotential
clinic,arincluding
aspects
biologic
fháil
na
galair
éagsúla
chun
coir
leighis
that
can be realised
focused infusion
out through
inna
thedaoine
accredited
atherapy
bhaintcarried
amach
bhionn
application
of basicdo
research.
Theadevelopment
suite
that
provides
optimal
care
forlike-minded
RA
agafulaingt
de bharr
nadepend
galair on
seo.
Tá anof
smart economy
will
patients.
In
addition
to
lectures
from
collaborative
partners
identifying
opportunities
chuid taighde tabhachtach ar siúl Conway
anseo
Fellows,
Professors
Oliver
FitzGerald
and
and
realising
basic
and
applied
research
san
institiúd
a d’fhéadfadh
tionchar
synergies.
This
collaboration,
initiated
through
Douglas Veale, delegates heard from clinical
mhor
a bheithsupplement,
aige ar shaol
daoinethe
inár
anurse
SFI research
highlights
specialists about patient
education,
potential
that
innovative
indigenous
companies
screening
and
monitoring
of biological
working with academia can realise.”
tract is lined with cells that block the contents
ofa the
gut from ar
leaking
into theseo
intestine.
In an
dhéanamh
an taighde
tri mhean
IBD patient, this barrier is broken and the
na Gaeilge le mhuintir na Gaeilge. Bígí ag
contents of the gut leak out into surrounding
Addressing
the
international
guests,
Mary
faire
amach
don
chlár
nua
‘IsConway
eolaíMsmise’
areas.
The
research
team in
UCD
used
Duff,
Director
of Nursing
and
Kayclass
Radio
inaMs.
dteannta
is of
aar
model
of na
IBDGaeltachta,
and,
by applying
a new
Connolly,
Assistant
Directorinhibitors,
of http://www.
Nursingwere
for the
drugs
known
as hydroxylase
féidir
é a fháil
ar podcast
ar
able
to &
almost
reverse
Bone
Joint completely
Unit expressed
theirthehope that
rte.ie/rnag/arstraesatsaotharlann.html
symptoms
of theof
disease.
the experience
the multidisciplinary team
from St
wouldnew
provide
template
“When
weVincent’s
applied these
drugsa to
our IBDfor
model,
the
gut
was tricked
into thinking
delegates
to reproduce
similar
care andthat it
Robert
Lumsden
was being deprived of oxygen. This activated
facilities for the management of RA patients in
protective pathways, which in turn prevented
their
respective
countries.
the death
of the cells
that line the
gastrointestinal tract,” explained Professor
Taylor. “Our pre-clinical trial data can now
inform the next phase Sigmoid Pharma product
development pipeline”.
Guiding Conway
scientists
through the
glycan
maze Award
collaborator
scoops
Irishanalysis
Times Innovation
therapies.
Taylor’s collaboration with Sigmoid Pharma has
certainly been successful by these metrics with
three co-authored publications to date in two of
In addition to the product that is currently in
the highest ranking scientific journals in the
tract
lined
cells
that
block the contents
results
in both
academic outputs
and the
Postdoctoral researchers from the
features
of therapeutic
the is
type
ofwith
data
each
provides.
phase
II clinical
studies,
Sigmoid
Pharma is
field,
Gastroenterology
andglycoproteins
Proceeding of and
the
of the gut from leaking into the intestine. In an
application
of
research
toward
clinical
product
company,
Sigmoid
Pharma
recently
scooped
The Sigmoid
Pharma-Taylor
collaboration is
National
Institute
for Bioprocessing
to establish
connections
between
developing a LEDDS™-enabled formulation of
National
Academy
of Sciences,
as well glycan
as the
IBD
patient,
this
barrier
is
broken
development
with
indigenous
companies.”
the
overall
Innovation
of
the
Year
award
at
facilitating the
development
of a new
Research
& Training,
under
the
structure and
their functions.
They
classify the
approaches and the
the
hydroxylase
inhibitor
generation
of proprietary
innovative products
contents of the gut leak out into surrounding
the inaugural
Irish
Times
All-Island
therapeutic
approach
for the
treatment of
supervision
of
Conway
Fellow,
dimethyloxaloylglycine
(DMOG)
to are
bring
and
the creation
of high-skilled
jobs.
according to whether
glycans
in about
Commenting
on the
Taylor collaboration,
Dr
areas. The research team in UCD Conway used
Innovation Awards.
The life-science
SME,
inflammatory
bowel disease
by bringing
Professor
Pauline
Rudd, (IBD)
published
a Dr
effective,
safe and targeted
of this
However,
face a number
intact glycoproteins,
aredelivery
chemically,
Coulter
said,researchers
“The collaboration
with the Taylor
a model of IBD and, by applying a new class of
founded the
by UCD
pharmacology
graduate,
More than 15,000 people in Ireland and
together
research
methodology
of
the
potential
therapeutic
agent.glycans or are
review
ofofavailable
technologies
laboratory
clearly
the potentialthe
of
challenges
in demonstrates
relation
glycan
enzymatically
released
An image
the
peptide
structurefor
central
variety
of
in ordertoto
drugs
known as hydroxylase
inhibitors, were
Ivan
Coulter,
hasfrog
actively
collaborated
with
millions
of solutions
people worldwide
areunderstand
living with the
Taylor
group
with
the proprietary
that
can be
realised through
focused
protein
glycosylation
analysis
in the
analysis
primarily
to the
diversity
glycoproteins
themselves.
Each
to the work
of adrug
UCDdelivery
Conway
research
team
able
to almost completely
reverse
theapproach
Conway
Fellow,
Professor
Cormac
Taylor
structural
basis
for due
the
difference
in biological
symptoms
IBD
today.
Current
therapeutic
liquid/emulsion
system,
application
of
basic
research.
The
development
October
issue
of
Nature
Chemical
of
molecular
structure,
construction
can
give
complementary
information
so
symptoms
of
the
disease.
since
being
granted
afront
Science
options
for
this
chronic
debilitating
disease
are
was selected
as the by
coverFoundation
image for the
LEDDS®,
developed
Sigmoid
Pharma.
activity.
of
a smart economy
will depend
on like-minded
Biology.
sequence
extent
of possible
it is important at the outset to decide
Ireland
industry
research
partnership
award
very
limitedand
withthe
surgery
often
being the only
April 2010
edition
of the scientific
journal,
“When
we
applied
these
new
drugs
to
our
IBD
collaborative
partners
identifying
opportunities
Commenting
on the award, Professor Taylor
linkages
withThe
lipids
or peptides.
the level of data required, whether
in 2004.
viable
option.
Sigmoid
product, currently
Thisrealising
particular
XT-7
peptide,
from the
Biochimica
Biophysica
(BBA);and his
model, the gut was tricked into thinking that it
and
basic
and
appliedisolated
research
said,
“We areetdelighted
for Acta
Dr Coulter
Additionally,
naturally
quantitative or qualitative data is needed
in
a phase
II clinical
study,occurring
uniquely
enables for
Glycosylation,
the
most
common
postThe
Irish
Times
award
recognises
the
stellar
skin
of
Silurana
tropicalis,
shows
potential
was being deprived of oxygen. This activated
synergies. This collaboration, initiated through
Proteins
Proteomics.
team
and &
indeed
it reflects well on our
oral
delivery of aare
powerful
drug
without
glycoproteins
typically
only
present
and how much biological material is
translational
modification
conferred
innovative performance
of Sigmoid
Pharma in
protective pathways, which in turn prevented
adrug
SFI research supplement,
theactivity
as it hashighlights
impressive
partnership. A key driver of successful
causing
systemic
side-effects.
at lowdevelopment
levels
and,
currently,
therecompanies
is no
available
their
application
of research
and
development.
on
proteins,
is skin
the
feature
that
most
Peptides
in the
many
species
of frog
the
death offor
theanalysis.
cells that line the
potential
thatgrowth
innovative
indigenous
scientific
research
in of
2010
is meaningful
against
the
of
bacteria
and
Candida
universal
method
for can
rapid
and reliable
The
has
developed
two new
drug
influences
the
function
of industry
proteins
gastrointestinal tract,” explained Professor
working
with
realise.”
havecompany
anti-bacterial
and anti-fungal
properties
normal
conditions,
the
gastrointestinal
May 2010.qxd:Layout
1academia
copy
07/05/2010
Page
3 academia
interaction
of
with
that 13:12 Under
albicans.
However,
this
potential
as
an
antitechnologies,
LEDDS™
and
SmPill™,
which
not
identification
of
glycan
structure.
and
their
Due to
This work
made trial
possible
through
Taylor.
“Our was
pre-clinical
data can
now
as well
as biological
thethe
ability
toactivity.
lyseand
or rupture
Taylor’s
with Sigmoid
Pharma has
only enhance
solubility
permeability of
infectivecollaboration
agent is restricted
by its haemolytic
their
diversity,
glycans
are finely-tuned
funding
Science
Foundation
inform
thefrom
next phase
Sigmoid
Pharma product
mammalian
cells.
This innate
immunity
certainly
been
successful
by
these
metrics
with
the
drug
but
can
deliver
it
to
targeted
locations
Inactivity.
reality, it is the research goals of
development
information
carriers and
there
is now of
a
Ireland, thepipeline”.
EU FP6 Glyfdis and Eurospan
protects
it from attack.tract,
These
properties
three
co-authored
publications
to date the
in two of
in
the gastrointestinal
including
the
the particular
project
that dictate
renewed
emphasis on their
analysis.
programmes,
the
Royal Society and
In
addition
to
the
product that is currently in
the
highest
ranking
scientific
journals
in
the
colon.
frog skin peptides are exciting from the
A change
to the amino
acid structure
of the
most
appropriate
method
of analysis.
ChiefIIScientific
OfficeSigmoid
of the Scottish
phase
clinical
studies,
Pharma is
field,
Gastroenterology
and
Proceeding
of
the
prospect
of being
developedcollaboration
into
Researchers
must
not only
be
aware
XT-7 peptide
can create
an analogue
Government.
The
Sigmoid
Pharma-Taylor
is
With
specific
changes
in the
glycosylation
developing
a LEDDS™-enabled formulation of
National
Academy
of Sciences,
as wellthat
as the
therapeutically
valuable
anti-infective
and antiof
the techniques
available
but
facilitating
the development
of &
a new
retains
anti-infective
properties
butwhat
without the
process
occurring
in health
disease,
the
hydroxylase inhibitor
generation
of proprietary
innovative
products
Reference
cancer agents.
therapeutic
approach
the treatment
information
these
techniques
or
glycan
analysis
can for
provide
both of
dimethyloxaloylglycine
(DMOG)
to bring about
and
the creation
of high-skilled
jobs.
complicating
haemolytic
activity.
The single
A systematic approach to protein
glycosylation
inflammatory
bowel
disease
(IBD)
by
bringing
Meta-analysis
by
UCD
researchers
led
by
of
HIV
areand
critical
in maze.
determining
the
studies
in
humans
have
shown
that
non
combination
of
techniques
will
provide.
effective,
targeted
delivery
thisrate
diagnostic
and Dr
prognostic
information.
analysis:nef
asafe
path
through
the
Karina of
Mariño,
amino
acid15,000
substitution
(glycine
replaced
by
Conway Fellow,
Fellow,
Chandralal
Hewage
andhas
his
More
than
people
in
Ireland
and
together
the research
methodology
of the
Conway
Professor
Denis
Shields
of
disease
progression.
Professor
progression
was
associated
with
gross
The authors succinctly stratify the major
potential
therapeutic
Jonathan Bones,
Jayesh agent.
J Kattla, & PaulineDenis
M
It is also useful in drug discovery and
millions
ofinpeople
worldwide
arefor
living
withofthe
lysine) improves
the
therapeutic
potential
team carried
out there
molecular
of the
Taylor
groupthat
with
the proprietary
determined
is nomodelling
evidence
Shields
searches
for modifiers
of
deletions
theroutinely
nef
gene.
technologies
used
structural
Rudd.
Biology
(October
2010)
CoverNature
ofbelieves
AprilChemical
2010that
edition
of Biochimica
et
Biophysica
production
to
comply
withclear
regulatory
symptoms
IBDoccurring
today. Current
therapeutic
liquid/emulsion
drug
delivery
that
particular
defective
viralsystem,
sequences
in a
progression
rates should
now focus on other
XT-7
peptide
and
its
analogue
[G4K]XT-7
in
this
naturally
peptide.
doi:10.1038/nchembio.437
Acta
(BBA);
Proteins
&
Proteomics.
Nand
O-glycan
analysis
and
describe
requirements
for monitoring
critical
However,
of the research
in the
area to
options
formuch
this chronic
debilitating
disease
are
LEDDS®,
developed
Sigmoid
Pharma.
the
HIV-1 nef
gene orbycertain
regions
of the
host and viral factors. “Systematic evaluation
date limited
has been
based
on observational
or only
case
very
with
surgery
often being the
protein play a significant role in disease
of large quantities of data by bioinformatics
Commenting on the award, Professor Taylor
studies
rather
than
rigorous,
systematic
viable
option.
The
Sigmoid
product,
currently
progression.
can be just as important in refuting
said, “We are delighted for Dr Coulter and his
scientific
This work
by doctoral
in
a phaseevaluation.
II clinical study,
uniquely
enables
hypotheses that are current in the literature, as
team and indeed
it reflects
on our on
HIV-infected
patients
can bewell
categorised
candidate
Ravindra
Pushker
set
out
to
oral delivery of a powerful drug without
it is in discovering unknown patterns”, he said.
partnership.
A key
driverof
ofyears
successful
the basis of the
number
it takes for
determine
in
a
substantially
larger
sample
set
causing systemic side-effects.
scientific
researchto
in AIDS.
2010 is
meaningful
them to progress
Some
patients
if any association exists between disease
This research was funded through Science
Under
normal
conditions,
the
gastrointestinal
interaction
of
academia
with
industry
that
maintain
stable
CD4
lymphocyte
counts
and
progression
and
particular
amino
acidthe
Foundation
andthat
University
College
tract
is lined Ireland
with cells
block the
contents
results
in both
academic
outputs
and
Irish biopharmaceutical development
will
examine whether vitamin D2 In an
Conway
DrPharma
Lorraine
Brennan
and
nmol/l
is prevalent
intoward
as much
of
do not goFellow,
on
to develop
AIDS
even
after
more
differences
orresearch
deletions
within
the as
nefhalf
gene.
ofDublin.
the gut from leaking into the intestine.
application
of
clinical
product
company,
Sigmoid
recently
scooped
enhanced
mushrooms
can
actually
UCD
colleagues,
Dr Anne
andat
European and
USindigenous
populations.
There is
thanoverall
10
years
of infection.
IBD patient, this barrier is broken and the
development
with
companies.”
the
Innovation
theNugent
Year award
On
a per by
patient
basis, there
excess of
A new fortnightly
forumoffor
Conway
graduate
decided
the
members
butwas
it isno
envisaged
([email protected] ) and postdoctoral
increase
ofsurrounding
vitamin D
Professor
Mike
Gibney
from
the
Institute
accumulating
evidence
suggest
thatnef
contents
ofcirculating
the gut leaklevels
out into
the inaugural
Irish
Times
All-Island
Scientists
are
curious
as to
why
these
longLTNP
patients
with
one
orofto
more
defective
and
postdoctoral
researchers
will
be
launched
that
it
will
include
a
mix
technology
researchers,
Dr David
Commenting
on
the
Taylor
collaboration,
Dr
areas.
The research
teamGomez
in aUCD
Conway
used
Innovation
Awards.
The
life-science
SME,
(25(OH)D)
and provide
novel
vehicle
of
Food
and
Health
have
been
awarded
vitamin
D
status
may
play
a
role
in
the
term,
nonprogressor
(LTNP)
patients
do
not
sequences
when
compared
to
progressors.
Coulter
said,
“The
collaboration
with
the
Taylor
in May 2010.
Thispharmacology
initiative will give
early- Dr
overviews, informal and formal research
([email protected])
and Dr Craig
Slattery
aReference:
model
of IBD
and, byof
applying
a new
class of
founded
by
UCD
graduate,
for
dietary
delivery
vitamin
D.
funding
from
Monaghan
Mushrooms
development
of
diseases
those
develop AIDS.
This
may reflect
differences
in
While the high
frequency
of beyond
amino
acid
laboratory
clearly
demonstrates
the
potential
stageCoulter,
researchers
the opportunity
to talkwith
about
seminars, PhD viva rehearsals and career
([email protected]
) invite
for
Meta-analysis
test
the association
ofsuggestions
HIV-1 nefwere
amino
drugs
knowntoas
hydroxylase
inhibitors,
Ivan
has
actively
collaborated
theperform
host, viralresearch
genetics
or environmental
replacement
at particular
residues
is indicative
that
can be
through
focused
to
their
vitamin
D
related
to realised
bone
acid
and
deletions with
disease
progression.
able
to
almost
completely
reverse
the
Conway
Fellow,
Professor
Cormac
Taylor
sciencethat
and
issues
thaton
concern
them
in an
development
talksmetabolism.
from
within
and
beyond
thedifferences
forum
schedule.
factors
could
potentially
be
exploited
for
of
rapid
evolvement,
permutation
testing
application of basic research. The development
Ravindra Pushker, Jean-Marc Jacquē, Denis C. Shields.
enhanced
mushrooms.
symptoms
of the disease.
since
being
granted
a with
Science
Foundation
informal
environment
refreshments
academia.
Forum
committee
members,
PhD
the
treatment
of the disease.
showed
that
residues
with
more
replacements
Journal of Virology, Apr 2010 p3644-3653
of
a smart
economy
will
depend
on
like-minded
Meta-analysis
byresearch
UCD researchers
by
of HIV nef are critical in determining the rate
studies
have
shown
that
non
There
isinMr
ahumans
real
need
forstatistically
enhancing
Ireland
industry
partnership
provided!
Content
for the forum
willled
beaward
student
Thomas
Schwarzl
than
expected
were
not
significant.
“When
we applied
these new
drugs to
our IBD
collaborative
partners
identifying
opportunities
Conway
Fellow,
Professor
Denis
Shields
has
of disease
progression.
Professor
Denis
progression
was
associated
with
gross
Studies
in
model
organisms
have
that
in
2004.
The
major
source
of vitamin
Dshown
is
dietary
intake
and
vitamin
Dresearch
2 enhanced
model,
gut was
tricked
into for
thinking
that itof
and
realising
basic
and
applied
determined
that
there recognises
is novirus
clear
evidence
Shieldsthe
believes
that
searches
modifiers
deletions
in the
nef
gene.
infection
with
nef-deficient
shows
an
The
researchers
conclude
that
current
data
The
Irish
Times
award
the
stellar
sunlight
with defective
diet providing
a limited in
mushrooms
represent
a novel
vehicle
was
being deprived
of oxygen.
synergies.
This
collaboration,
initiated
through
that
particular
viral
sequences
progression
rates should
now This
focusactivated
on other
provides no
evidence
that individual
residues
attenuated
course of infection
and
some
innovative
performance
of
Sigmoid
Pharma
in
However,
muchsupplement,
of the research
in the the
area to
source.
Vitamin
Dor
deficiency,
reflected
vitamin
D intakes.
protective
pathways,
which
in turn prevented
afor
SFIincreasing
research
highlights
the HIV-1
nef gene
certain
regions
of the
host and viral
factors.
“Systematic
evaluation
their
application
of research
and
development.
date has that
been
basedtheir
on indigenous
observational
or case
the
deathquantities
of the cells
that
line
the
potential
innovative
companies
by
circulating
25-hydroxyvitamin
D
However,
to
date,
efficacy
has
protein
play
a
significant
role
in
disease
of
large
of
data
by
bioinformatics
The company has developed two new drug
studies
rather
than
rigorous,
systematic
gastrointestinal
tract,”
explained
Professor
working
with
academia
can
realise.”
progression.concentrations
can be just as important in refuting
[25(OH)D]
less than
50 not
not
been demonstrated. This study
technologies,
LEDDS™ and SmPill™,
which
scientific evaluation. This work by doctoral
Taylor.
“Our pre-clinical
trial data
can
now
hypotheses
that are current
in the
literature,
as
Taylor’s
collaboration
with Sigmoid
has
only
enhancepatients
the solubility
permeability
HIV-infected
can beand
categorised
on of
candidate
Ravindra Pushker
set outPharma
to
inform
the
next phase
Sigmoidpatterns”,
Pharma product
it
is
in
discovering
unknown
he said.
certainly
been
by larger
these metrics
with
the
cannumber
deliver it
targeted
locations
the drug
basisbut
of the
ofto
years
it takes
for
determine
in asuccessful
substantially
sample set
development pipeline”.
three
to date
in two of
in
the to
gastrointestinal
tract,Some
including
the
them
progress to AIDS.
patients
if anyco-authored
association publications
exists between
disease
This research was funded through Science
InFoundation
addition toIreland
the product
that is currently
the
highest
ranking
scientific
journals
in
the
colon.
maintain stable CD4 lymphocyte counts and
progression and particular amino acid
and University
Collegein
phase
II clinical studies, Sigmoid Pharma is
field,
Gastroenterology
Proceeding
of the
do not
go on Pharma-Taylor
to develop AIDS
even after more
differences
or deletionsand
within
the nef gene.
Dublin.
The
Sigmoid
collaboration
is
developing a LEDDS™-enabled formulation of
National Academy of Sciences, as well as the
than 10 years
infection. of a new
facilitating
the of
development
On a per patient
basis, there
was noproducts
excess of
the hydroxylase inhibitor
generation
of proprietary
innovative
therapeutic
approach
thewhy
treatment
of
Scientists are
curious for
as to
these longLTNP
one or morejobs.
defective nef
dimethyloxaloylglycine (DMOG) to bring
and
thepatients
creationwith
of high-skilled
Elaineabout
Quinn
inflammatory
bowel disease
(IBD)
by bringing
term, non- progressor
(LTNP)
patients
do not
sequences when compared to progressors.
effective, safe and targeted delivery of this
Communications
&
Education
Officer
More
than
15,000
people
in
Ireland
and
Reference:therapeutic agent.
together
the research
methodology
of the in
develop AIDS.
This may
reflect differences
While the high frequency of amino acid
potential
Meta-analysis
to test the association
of HIV-1 nef
amino
Conway
of Biomolecular
& Biomedical
Research
millions
of people
worldwide
are living
with
the Institute
Taylor
group
the proprietary
the host,
viralwith
genetics
or environmental
replacement
at particular
residues
isUCD
indicative
acid differences and deletions with disease progression.
symptoms
IBD today. permutation
Current therapeutic
liquid/emulsion
drug
delivery be
system,
University
College
Dublin
factors that could
potentially
exploited for
of rapid evolvement,
testing
Ravindra Pushker, Jean-Marc Jacquē, Denis C. Shields.
options
chronicwith
debilitating
disease are
LEDDS®,
developed
by Sigmoid Pharma.
Belfield, Dublin 4
the treatment
of the disease.
showedfor
thatthis
residues
more replacements
Journal of Virology, Apr 2010 p3644-3653
very
with
surgery
often beingsignificant.
the only
than limited
expected
were
not statistically
Ireland
Commenting
on the
award, Professor
Taylor
Investing
Your
Future
Studies
in in
model
organisms
have shown
that
viable option. The Sigmoid product, currently
said,
“We
are
delighted
for
Dr
Coulter
and
his
infection with nef-deficient virus shows an
The
researchers
conclude
current
data
in
a phase
II clinical
study, that
uniquely
enables
E: [email protected]
team
and indeed
reflects
welland
on some
our
provides
no of
evidence
that drug
individual
residues
attenuated
courseit of
infection
oral
delivery
a powerful
without
T: (+353-1) 716 6706
partnership. A key driver of successful
causing systemic side-effects.
F: (+353-1) 716 6701
scientific research in 2010 is meaningful
Under normal conditions, the gastrointestinal
interaction of academia with industry that
W: www.ucd.ie/conway
Frog peptide structure selected for journal cover
Bioinformatic analysis of HIV progression studies
Conway
collaborator
scoops
Irish Times
Innovation
Award
Investigating
effects
of vitamin–D
enriched
mushrooms
in the
diet
Launch of Conway
postdoctoral
&2 graduate
forum
Bioinformatic analysis of HIV progression studies
December
2010
Issue
May 2010
Issue
10112
september
2007
Issue
Conway collaborator scoops Irish Times Innovation Award
Is Eolai Mise
Success in EU FP7 call
disease (CKD) and improve patient treatment,
Conway researchers led by Dr. Tara
McMorrow and Professor Michael Ryan have
with particular focus on CKD arising from
May
2010.qxd:Layout
1 copy
07/05/2010
13:12
3
diabetes
and Page
hypertension.
The multisuccessfully
secured €485,500
in funding
as
disciplinary research consortium has 25
part of an overall award to the Systems
partners (16 universities, 9 industry partners)
Biology towards Novel Chronic Kidney
from 15 countries and the project is due to run
Disease Diagnosis and Treatment (SysKid)
for five years.
consortium under the European Union FP7
programme.
The UCD Conway team, including postdoctoral
researchers Dr. Craig Slattery and Dr. Natalia
Syskid (www.SysKid.eu) was established to
Martin, will utilise cell culture and animal
further our understanding of chronic kidney
models to identify processes involved in early
CKD progression and investigate novel
strategies for preventing and slowing the
progression of the disease. These studies will
be integrated with clinical and epidemiological
studies across the consortium using systems
biology methodologies in order to develop new
diagnostic strategies and treatment options to
prevent CKD development. Email
[email protected] for details of a PhD
position currently available.
GlycoExtractor advances glycan data manipulation
Success in EU FP7 call
Glycomics needs the supporting framework
cells, tissues and fluids.
EUROCarbDB, a research infrastructure design
study
funded byInnovation
the EU 6th Framework Award
of extensive, well-curated databases
and
Conway
collaborator
scoops
Irish
Times
Commercial
packages2that
support HPLC
Worm
research
reveals
cilia
disease
gene
function
Role
for
CO
sensor
identified
flexible analytical
tools. Currently,
thiscellular
field
Programme.
Prospective
users can access the
models to identify processes involved in early
disease
(CKD)
and improve
treatment,
Conway researchers led by Dr. Tara
instruments
cannot
facilitatepatient
the extraction
of
of study lacks the established,
GlycoExtractor
tool
CKD
progression
andoninvestigate novel
McMorrow and Professor Michael Ryan have
with
particular
focus
on In
CKD
arising
from
large
quantities
of
data.
an
effort
to
alleviate
http://glycobase.nibrt.ie:8080/DemoGlycoExtra
comprehensive and centralised data
strategies
for
preventing
and slowing
diabetes
and
hypertension.
The multithis
bottleneck
within
high-throughput
successfully
secured
€485,500
in
funding
as
tract
is
lined
with cells
that
the contents
results
in
both
academic
outputs
and
the
Irish
biopharmaceutical
development
UCD
Conway
researchers
have
found
CO
sensor
associated
with
antiof
articles
published
in block
thethe
issue
of
2
collections, standards
and
information
ctor/mainPage.
Research
by
Fellow,
the
function
of
worm
Arl13b
causesproduct
the progression
complex
including
diabetes,
thetraits
disease.
These
studies
will In an
disciplinary
research
has
25 clinical
part of anprotocols
overall
award
to Conway
the
Systems
glycomic
theconsortium
team
have
of
theof
gut
from
intoobesity,
the intestine.
application
ofNIBRT
research
toward
company,
Sigmoid
Pharma
recently
scooped
that
carbon
dioxide
(CO
)Dr
is Oliver
not
only projects,
inflammatory
and
immunosuppressive
the
Journal
ofleaking
Immunology;
a further
reporting
that
exist
within
Reference
2
with
clinical
and
Blacque
has
revealed
ciliary
membrane
to bulge
and
become be integrated
mental
retardation
andepidemiological
even
cancer.
developed
adevelopment
web-based
tool
that
interfaces
(16
universities,
9 industry
partners)
Biology towards
Novel
Chronic
Kidney
IBD
patient,
this barrier
broken
and the
with
indigenous
companies.”
the
overall
Innovation
ofnew
the information
Yearand
award
at
A web-based of
interface
for high
genomics
and involved
proteomics.
in
climate
change
apartners
signalling
may
exist.
We
found
that GlycoExtractor:
endorsement
the isusing
research.
across
the
with the
Waters
chromatography
about
a gene
implicated
in Joubert from
misshapen
as well
as software
affecting
of
contents
of consortium
the
gut leak out
intosystems
surrounding
the inaugural
Irish
Times
All-Island
15 countries
and the
project
is due tothe
runabilitystudies
Disease Diagnosis
and
Treatment
(SysKid)
processing
of HPLC-Glycan
data
throughput
on
the
Taylor
collaboration,
Drbiology
waste
product
of
respiration
inSME,
cells
elevated
levels
of
COthe
had
a profound
Dr Oliver
hopes
these
findings
in P.
order
to
develop
new
package
to Commenting
improve
and
automate
export
Researchers,
Dr
Natalia
Artemenko
and
Dr
2 distribute
Natalia V.methodologies
Artemenko,
Matthew
Campbell,
and
Pauline
areas.
The Blacque
research
team
inthat
UCD
Conway
used
Innovation
Awards.
The
life-science
for
five years.
consortium under
the European
Union
FP7
syndrome
and
related
cerebellar
disorders
other
proteins
to collaboration
properly
within
Coulter
said,
with
the Taylor
diagnostic
strategies
and
treatment
options
M. Rudd Journal
of of
Proteome
Research,
2010,
9
ppclass
but
alsobycharacterised
plays
an active
role
in regueffect
on
a “The
master
pathway
part
ofIBD
their
wider
programme
of of
will
ultimately
lead
to applying
a greater
Matthew
Campbell
from
the
National
Institute
ofbone
data to various
file
formats
forsignalling
subsequent
aAs
model
and,
by
a (4),
newto
founded
UCD
pharmacology
graduate,
Dr
programme.
(JSRDs),
by blindness,
the
ciliary
membrane.
laboratory
clearly
demonstrates
the
potentialprevent
2037–2041
The
Conway
team,
including
postdoctoral
CKD
development.
Email
analysis.
modular
architecture
ofEoin
the tool
of Bioprocessing
Research
&
Training
(NIBRT)
understanding
only
of JSRDs,
butwere
also
lating
the genes
involved
in inflamcalled
NF-ĸB”,
said Dr
Cummins,
research,
Professor
Cormac
Taylor
drugs
known
as not
hydroxylase
inhibitors,
Ivan
Coulter,
has
actively
collaborated
with UCD The
abnormalities,
cystic
kidneys,
that
can
beSlattery
realised and
through
focused
researchers
Dr.the
Craig
Dr.
Natalia
Syskid
(www.SysKid.eu)
was established
to
[email protected]
forciliopathies
detailsreverse
of asuch
PhD
led
by Conway
Fellow, Professor
Pauline
Rudd
also facilitates
manipulation
of
data
fromlead
able
to
almost
completely
theaas
Conway
Fellow,
Professor
Cormac
Taylor
They
also
found
that
a
fully
functional
of
closely
related
mation
and
innate
immunity.
Their
postdoctoral
researcher
and
and
Dr.
Eoin
Cummins
hosted
2-day
developmental
delay
and
loss
of
muscle
application
of
basic
research.
The
development
Martin,
will
utilise
cell
culture
and
animal
position
currently
available.
further
our
understanding
of
chronic
kidney
have developedsince
an open
other data management
systems.
symptoms
of the
disease.
beingaccess,
grantedweb-based
awere
Science
Foundation
Arl13b
protein
ispublication.
needed
for the
Meckel Gruber
and
Bardet-Biedl
syndrome,
research
findings
highlighted
in
author
oneconomy
this
conference
that
focused
on therapeutic
of
a smart
will depend
onnormal
like-minded
tone
and
control.
The
findings
of this
interface that facilitates
extraction,
querying
Ireland
industry
research
partnership
award
st
functioning
of
a
protein
transport
system
in
as
well
as
perhaps
more
common
The
NIBRT
team
are
now
working
to
integrate
“When
we
applied
these
new
drugs
to our IBD
collaborative
partners
identifying
opportunities
aspects
of
hypoxia-inducible
pathways.
the
October
1
issue
of
the
Journal
of
a Science
and sharing of research,
HPLC-glycan
datathrough
generated
in
in
2004. funded
GlycoExtractor
with
EUROCarbDB
cilia.
Thisthe
intraflagellar
transport
system
phenotypes
with
model,
the gutassociated
was
tricked
intocilium
thinking
and
realising
basic
and
applied
research
Sponsored
by
the
HypoxiaNET
EUthat it
Immunology.
In
previous
work,
the
Taylor
group
high throughput
processes.
Foundation
Ireland
President
of
Ireland
The Irish Times award recognises the stellar
framework synergies.
to
provide
a comprehensive
highwas
being
deprived
ofmeeting
oxygen. retardation
This
activated
This
collaboration,
initiated
through
(IFT)
makes
contact
with
the
ciliarymaster
dysfunction
such
as
mental
and
COST
action,
the
attracted
demonstrated
that
the
NF-ĸB
Young
Researcher
Award
(PIYRA)
to
Oliver
of Sigmoid Pharma
in
Glycosylation isinnovative
the mostperformance
common and
throughput
HPLC
data analysis
for
protective
pathways, which in turn prevented
amembrane.
SFI research
supplement,
highlights
the
Based
onplatform
these
results,
they
obesity.
more
than
100
scientists
from Europe,
The
of oxygen
(O
) and carbon
signalling
is
induced
by
their levels
application
of research
Blacque,
were
recently
published
in the
the storagepotential
2and development.
and annotation
of experimental
structurally diverse
post-translational
the
death
of the
cells
that line the
thatpathway
innovative
indigenous
companies
proposed
a newOworking
model for Arl13b,
The
company
has
developed
new drug
the
USA “That
and Korea
toassociates
UCD Professor
Conway
dioxide
(CO
) in
cells
vary
hypoxicwith
(low
) conditions.
of
Cell
modification ofJournal
proteins.
More
than
halfcan
oftwo
all
data. The integration
of next
gastrointestinal
tract,”
explained
working
academia
can realise.”In this
He notes
Arl13b
with ciliary
2 Biology.
2generation
Glycomics needs
the supporting
framework
cells,
tissues
and fluids.
EUROCarbDB,
a research
infrastructure
design
where
it
functions
at
the
ciliary
membrane
th
technologies,
LEDDS™
and
SmPill™,
which
not
bioinformatic
tools
will
further
the
gene products dramatically
have been shown
to
be
Institute
October
7th
&
8can
2010.
in
health
and
in
diseases
study,
the
researchers
now
show
that
Taylor.
“Ouron
pre-clinical
trial
data
now
membranes
and
is
required
for
of extensive, well-curated
databases
and
study
funded by the EU 6th Framework cilium
Taylor’s
collaboration
with
Sigmoid
Pharma
has
only
enhance
the
solubility
and
permeability
of
One
of
seven
genes
associated
with
JSRDs,
to
regulate
important
ciliary
membrane
development
of unifiedprotein
approaches
for within this
glycosylated. With
many
specificinflammation,
glycans or
inform
the next phase
Sigmoid
Pharma
product
Commercialapackages
that
support
HPLC
The
delegates
heard
and
discussed
such
as but
chronic
ischemia
central
regulator
structure/function
in
both
worms
and
Programme.
Prospective
users
can
access
the
flexible analytical
tools.
Currently,
this
field
certainly
been
successful
by
these
metrics
with
the
drug
can
deliver
it
to
targeted
locations
Arl13bpotential
codes forasacancer
already known
to large
properties
such asthe
shape,
transmembrane
handling
scale facilitate
glycomics
data
initiatives
glycoforms showing
development
pipeline”.
instruments
cannot
extraction
oflevels inGlycoExtractor
the
latest
basic
science,thetechnology,
cancer
whereprotein
metabolism
rates
pathway,
IKKα reacts
to
CO
tooldemonstrates
on
of study lacks and
thethe
established,
mammals
remarkable
three
co-authored
publications
to
date
in
two
of
in
gastrointestinal
tract,
including
the
2
biomarkers, there
isroles
an increasing
need toand/or function
with
biomarker
discovery
play
in the formation
protein
distributions
and IFT.
largeapplications
quantities
ofindata.
In an effort
alleviate
comprehensive
and
centralised altered.
data
http://glycobase.nibrt.ie:8080/DemoGlycoExtra
pharmacology
and
translational
are
significantly
Elevated CO
a rapid,
reversible
andtodose
dependent
In
addition
to the
product
that
currently
in
the
highest
ranking scientific
journals
in theNIBRT
colon.
evolutionary
conservation
ofis
how
this small
researchers
Dr Matthew
Campbell
and
Dr
Natalia
develop high throughput,
highly
and
this2bottleneck within high-throughput
of
cilia, which
are sensitive
hair-like projections
collections, standards
and
information
ctor/mainPage.
This
research
was
partially
supported
by
phase
II clinical
studies,
Sigmoid
Pharma
is
field,
Gastroenterology
and
Proceeding
of the
Artemenko
who developed
GlycoExtractor
medicine
aspects
of
this
hot
topic
in
levels
that
occur
during
hypoventilation
manner.
Up
to
only
20
years
ago,
many
believed
G-protein
functions.”
robust strategies
that
detail
the
glycome
of
glycomic
projects,
the
NIBRT
team
have
The Sigmoid
Pharma-Taylor
extending
from
the
surfacecollaboration
of the cell. is
reporting protocols
that exist
within
a LEDDS™-enabled formulation of
National Academy of Sciences, as well as theReferencedeveloping
hypoxia
research.
of
intubated
patients
have
found
cilia to tool
be redundant
cellular
amost
web-based
that interfaces
facilitating
the precise
development
of a been
new
A web-basedinhibitor
interface for high
genomics and However,
proteomics.
the
molecular
detailsdeveloped
of
Reference
the
hydroxylase
generation of proprietary innovative productsGlycoExtractor:
with
the
Waters
chromatography
software
organelles
that have
fallen
victim
to
to
decrease
mortality
associated
with
Commenting
the
significance
processing
of HPLC-Glycan
data at
therapeutic
approach
fordoing
the
treatment
of
Joubert
syndrome
Arl13b functions
dimethyloxaloylglycine
(DMOG)
tociliary
bring about
and
the creation on
of high-skilled
jobs. of throughput
what
exactly
Arl13b
is
in cilia have
Researchers, Dr
Natalia
Artemenko
and
Dr
package
to
improve
and
automate
the
export
V.
Artemenko,
Matthew
P. Campbell,
and
Pauline
Natalia
inflammatory
bowel disease
by bringing
mammalian
evolution
- a type said,
of cellular
acute
respiratory
distress(IBD)
syndrome
or
the research,
Dr Cummins
“The M. Rudd Journal
membranes
andand
stabilizes
protein
transport
in
effective,
safe
targeted
delivery
of pp
this
remained
unclear.
of
Proteome
Research,
2010,
9
(4),
Matthew Campbell
from
the
National
Institute
of
data
to
various
file
formats
for
subsequent
More
than 15,000
Ireland
and
together the research methodology
ofinjury.
the
Caenorhabditis
elegans.agent.
Cevik S, Hori Y, Kaplan OI,
appendix.
We
nowpeople
knowinthat
these
cellular
endotoxin-induced
acute
lung
molecular
mechanism
of
this
CO
potential
therapeutic
2037–2041
2
analysis. The
modular
architecture
of the
of Bioprocessing
Research
& Training
(NIBRT)
millions
of people
worldwide
aretool
living with the
Kida K, Toivenon T, Foley-Fisher C, Cottell D, Katada T,
Taylor
group
with
the proprietary
Blacque’s
team
studied
the gene in thealso
ciliafacilitates
antennae
present
on of
nearly
all
of
our cells
sensor
may
an
alternative
led by Conway liquid/emulsion
Fellow, Professor
the manipulation
data
from
symptoms
IBDprovide
today. Current
therapeutic
Kontani K, Blacque OE. J Cell Biol. 2010 Mar 22;
drugPauline
deliveryRudd
system,
of
tiny
worms
(Caenorhabditis
elegans)
and
serve
fundamental
roles
in
many
COdeveloped
sensing
a feature
of other data management
therapeutic
route
indebilitating
those instances
have developedAcute
an open
access,
web-based
systems.
options
for this
chronic
disease are
188(6):953-69
LEDDS®,
byisSigmoid
Pharma.
2
on the research, Dr Kennedy
to die asand
a result
of the
raised including Commenting
New
research
led bycollaborators
Conway
Fellow
Dr University
while
the
ofmost likely very
motility
sensory
functions,
interface
that facilitates
extraction,
querying
specialised
cells
inintreatment
lower
animal species
when
suppressing
the
body’s
innate
limited
with
surgery
often
being
the only
The
NIBRT
team
are
now
working
to
integrate
glucose
levels
seen
in
diabetes.
Breandán
Kennedy
indicates
that
said,
“By
establishing a robust model for early
Commenting
ondata
theparallel
award,
Professor
Taylor
conducted
experiments
in
signalling
pathways
critical
to
development.
and sharing
of Tokyo
HPLC-glycan
generated
in
viable
option.
The
Sigmoid
product,
currently
May
2010.qxd:Layout
1
copy
07/05/2010
13:12
Page
3
such
asshould
flies
and
littleGlycoExtractor
immune
system
or inflammatory and late stage diabetic retinopathy, we would
with the
EUROCarbDB
of
diabetic
blindness
lookrodents
at for Dr but
said,
“We
are delighted
Coulter
his
high
throughput
processes.
a phase
IIisclinical
study,
uniquely
enables
cultured
human
Together,
theyand
Dr
Kennedyin
and
his team
found
that
new
blood
known
aboutitcells.
the
effect
response
clinically
desirable.
We
framework
to
provide
a comprehensive
highprotecting the is
neurons
for
colour
team
and responsible
indeed
reflects
wellof
onaltered
our vessels
It
is
now
not
surprising
that
defects
oral
delivery
of
a
powerful
drug
withoutin hope to better understand the progression of
and HPLC
the neuronal
cell death
in
diabetic
confirmed
that
Arl13b
proteins
uses
lipid
Glycosylation
is
the
most
common
and
throughput
data
analysis
platform
for
vision
in
the
eye
and
not
just
targeting
the
CO
onled
gene
expression.
This research
now
need
to
decipher
the
exact
the disease
and pave
the wayinvolved
for identifying
partnership.
A key
driver
disease
(CKD)
and
improve
patient
treatment,
models
to identify
processes
in early
Conway researchers
by
Dr.
Tara of successful
cilium
structure
and
function
are
associated
2
causing
systemic
side-effects.
retinopathy
can arise
independently
of each
anchors
to
associate
withfellow,
ciliary
structurally
diverse
the storage
and
annotation
experimental
blood
vessels
asProfessor
ispost-translational
currently
the
scientific
research
in practice.
2010
isthe
meaningful
CKD
investigate
novel
new progression
drug targets and
for its
successful
treatment”.
McMorrow
and
Michael
Ryan
have
with
particular
focus
onidentified
CKD
arising
from
group,
led
by
Conway
Professor
mechanisms
ofofthis
CO
-dependent
with
an
ever
expanding
range
of
human
other.
In
addition,
they
that
cone
2
modification ofmembrane.
proteins. More
than half
ofindustry
all
data. Theand
integration
of next
generation
Under
normal
conditions,
the
gastrointestinal
interaction
of academia
withblind
that
strategies for preventing and slowing the
diabetes
hypertension.
The
multisuccessfully
secured
€485,500
in funding
as effect
Cormac
Taylor
examined
the
of
intracellular
signalling
pathway”.
photoreceptor
neurons,
those
involved
in
Nearly
2.5 million
people
are
diseases
andfurther
syndromes,
called
The researchofwas
Sciencewill
bioinformatic
tools
will
thehas collectively
gene products
have
been worldwide
shown to be
progression
the funded
disease.through
These studies
disciplinary
research
consortium
25
partto
ofdiabetic
an overall
award
towork
the Systems
colour
vision
and
used
in
daylight,
are
most
due
retinopathy.
This
secondary
altered
CO
levels
on
gene
expression
in
Much
of
the
on
the
project
was
carried
ciliopathies,
which
have
overlapping
clinical
Foundation
Ireland
and theand
Health
Research
development of unified approaches for
glycosylated. With many specific
glycans or
2
be
integrated
with
clinical
epidemiological
partners by
(16the
universities,
9 industry
partners)
Biology towards
Novel Chronic
Kidney
high
glucose
levels.
complication
ofout
diabetes
the
growth
mammalian
cells
against
a background
The
work,
which
was
by and studies
by potential
UCDactivates
doctoral
candidate,
Sebihaaffected
features
such
as polycystic
kidneys
glycoforms showing
as cancer
handling large
scale
glycomics
datafunded
initiatives
Board. across the consortium using systems
from 15 countries and the project is due to run
Disease
Diagnosis
and Treatment
(SysKid)
of
new
leaky
blood
vessels
in
the
eye
and
is
biomarkers, there
is an
increasing
need to went onThe
with
applications
biomarker
discovery
of inflammation.
Science
Foundation
Ireland
and the biology methodologies
Cevik.
She
and herUnion
colleagues
tofive
livers,
retinal
degeneration,
bone
research
teamin
made
their observations
in order toEU
develop
new
Delegates at the HypoxiaNET
COST action
for
years.
consortium under
European
FP7
responsible
the the
death
of
photoreceptors,
NIBRT researchers Dr Matthew Campbell and Dr Natalia
develop highfor
throughput,
highly
and disrupting
using
a novel
zebrafish
model
of diabetes,
diagnostic
strategies
treatment
to 2010
demonstrate
inmessages
C. sensitive
eleganstohow
abnormalities,
hydrocephalus,
as well is
asArtemenko
Health
Research
Board
of
Ireland,
Arl13b
atinciliary
membrane
meeting
UCDand
Conway
Instituteoptions
in October
This
research
was
partially
supported
by
programme.
the
neurons
that
send
visual
our
Reference:
who
developed
GlycoExtractor
robust strategies that detail the glycome of
The
UCD
Conway
team,
including
postdoctoral
which
resembles
the
early
stages the
of
diabetic
prevent CKD development. Email
“Our results suggest that a molecular
highlighted
among
top ten percent
brain.
Predominant cone photoreceptor dysfunction in a
researchers
Dr.humans.
Craig Slattery
Dr. Natalia
retinopathy in
It is anand
exciting
Syskid (www.SysKid.eu) was established to
[email protected]
for details of a PhD
hyperglycaemic model of non-proliferative diabetic
development
for the
who
now
hope to
Until
now,
was unclear if of
thechronic
changes
to
Martin,
will utilise
cellgroup
culture
and
animal
position
currently
available.
further
ouritunderstanding
kidney
retinopathy.
Yolanda Alvarez,
Jenneth Chen, Alison
extend
theirinresearch
a non
vessels and neurons
occurredbyindependently
of led further
Meta-analysis
UCD researchers
by
HIV
nef are critical
in determining
the rate
studies
humans and
haveestablish
shown that
Reynolds, of
Nore
Waghorne,
John J. O’Connor,
Breandan
model
stage diabetic
disease. with gross
one other and which
of retinal
neuron
is Shields
Kennedy. Disease
Models
& Mechanisms
(2010) Denis
Conwaytype
Fellow,
Professor
Denis
has of late
of disease
progression.
Professor
progression
was associated
determined that there is no clear evidence
Shields believes that searches for modifiers of
deletions in the nef gene.
that particular defective viral sequences in
progression rates should now focus on other
larger
programmes
such as the new
MSc in
We
introduced
advanced
I amHIV-1
delighted
to welcome
you to the the
However,
much 4
ofnew
the research
in core
the area to
nef gene
or certain
host and
viralresearch,
factors. “Systematic
Commenting
on the
Dr Kennedyevaluation
likely to
die
as
a
result
of
the
raised
New research the
led by Conway
Fellow
Dr regions ofmost
date has been
based on
case
technology
modules
onobservational
a pilot basis or
this
Conway
Focus
and
look role
forward
to working
Imaging
commencing
in by
September
2010.
protein
play
a significant
in disease
ofestablishing
large quantities
of data
bioinformatics
glucose levels
seen
in
diabetes.
Breandán Kennedy
indicates
that treatment
said,
“By
a
robust
model
for
early
studies rather
than
rigorous,
systematic
academic
year;
those
covering
principles
progression.
can be
just
as
important
inblock
refuting
cells, tissues
and fluids.
EUROCarbDB,
a
research
infrastructure
design
Glycomics
the
supporting
framework
tract
is diabetic
lined
with
cells
the
contents
results
in both
academic
outputs
and the into
Irish
biopharmaceutical
with
you
in thelook
coming
months!
of
diabetic needs
blindness
should
at development
stage
retinopathy,
we
would
Welcome!
innovation
agenda
and
translation
2010
draws
to
athat
close,
I would
scientific
evaluation.
work
by
doctoral and lateAs
Dr Kennedyapplication
andpractical
his team
foundThis
that
newclinical
blood
hypotheses
are current
in initiatives,
the
literature,
as
study
funded
the
EU
6th
Framework
of
extensive,
databases
and
of
the by
gut
from
leaking
into
the
intestine.
of research
toward
product
company,
Sigmoid
Pharma
recently scooped
and
aspects
of
imaging
and
applied
protecting
thewell-curated
neurons
responsible
for
colour
Ibetter
hope
that
athat
number
of
new
hope to
understand
the
progression
of In an
HIV-infected patients can be categorisedCommercial
on
candidate
Ravindra
Pushker
set
out
to
clinical
application.
like
to
take
the
opportunity
to
packages
that
support
HPLC
anddevelopment
the neuronalwith
cellindigenous
death in diabetic
it ispatient,
in
discovering
unknown
patterns”,
Programme.
Prospective
users
access
flexible
tools.
Currently,
this
field
IBD
this
barrier
iscan
broken
and the
thehe said.
companies.”
the and
overall
Innovation
of
the
Year awardvessels
at
vision inanalytical
the eye
not
just
targeting
the
proteomics
began
in late
March
and
willset
run
the
disease
and
pave
the
way
for
identifying
the
basis
of
the
number
of
years
it
takes
for
determine
in
a
substantially
larger
sample
As
an
institute
with
an
increasingly
including
the
early-stage
researcher
forum
instruments
cannot
facilitate
the
extraction
of
issue
ofIrish
Conway
Focus
comesretinopathy
as
can arise independently of each
congratulate
Conway
on
of
study
lacks This
the
established,
GlycoExtractor
tool
on gut
contents
offor
the
leak outresearchers
into
surrounding
the
inaugural
Times
All-Island
blood
vessels
as is
currently
practice.
new
targets
its
successful
treatment”.
until
mid-June
a that
further
twodisease
modules
in drug
them
to
progressthe
to AIDS.
Some
patients
if anyof
association
exists
between
This
research
was
funded through
Science
large
data.identified
In with
an
effort
to
alleviate
Commenting
on
the
Taylor
collaboration,
Dr http://glycobase.nibrt.ie:8080/DemoGlycoExtra
other.quantities
In addition,
they
cone
interdisciplinary
research
focus
andSME,
described
in this
issue,
will
not
only
comprehensive
and
centralised
data
areas.
The research
team
in
UCD
Conway
used
Innovation
Awards.
The life-science
the
TCD-UCD
Innovation
Academy
As
we
define
the
research
roadmap
their
achievements
in
the
past
twelve
maintain
stable
CD4
lymphocyte
counts
and
progression
and
particular
amino
acid
Foundation
Ireland
and
University
College
this
bottleneck
within
high-throughput
Coulter
said,
“The
collaboration
theplace
Taylor
genomics
and
flow
cytometry
taking
photoreceptor
neurons,
those
involved
in with
Nearly 2.5 million
people
worldwide
are
blind graduate,
ctor/mainPage.
collections,
standards
and
information
astrengthen
model
of funded
IBD
and,
by applying
a new class of
founded
by
UCD
pharmacology
Dr
The research
was
through
Science
expertise
in
specialist
technology
platforms,
the
community
of
Conway
opens
its
doors
to
the
first
cohort
that
will
maximise
the
value
of
Conway
do
not
go
on
to
develop
AIDS
even
after
more
differences
or
deletions
within
the
nef
gene.
Dublin.
months;
a
tiny
fraction
of
which
are
glycomic
projects,
theclearly
NIBRT
team are
have
laboratory
demonstrates
the
andweek-long
used
in daylight,
most
due to diabetic
retinopathy.
This
secondary
over
periods
during
thepotential
summer
reporting
protocols
that exist
within
knownand
as hydroxylase
inhibitors, were
Ivan
Coulter,
has
actively
collaborated colour
with vision
Foundation
Ireland
Health
Research
Referencedrugs
we
are
placed
to
participatenew
indeveloped
the byathat
than
10uniquely
years
of infection.
researchers
andthe
forge
interdisciplinary
web-based
tool
that
interfaces
can be
realised
through
PhD
graduates
to embrace
research
by
tackling
big focused
questions
in Board.
highlighted
andnew
look
to
affected
the
glucose
levels.
complication
diabetes
activates
the
growth
interface
for
highforward
GlycoExtractor:
genomics
andofof
proteomics.
able
toA web-based
almost here,
completely
reverse
the
Conway
Fellow,
Professor
Cormac aTaylor
On
ahigh
per patient
basis,
there
was no excess
of
months.
with
the
Waters
chromatography
software
application
of
basic
research.
The
development
education
and
training
of
the
next
of new leaky blood
vessels
in
the
eye
and
is
processing
of
HPLC-Glycan
data
throughput
links
but
will
celebrate
and
heighten
culture
ofareinnovation
within
graduate
biology
and biomedicine,
fostering
symptoms
of the disease.
since
being
granted
Science
Scientists
curiousaas
to
whyFoundation
these
longLTNP
patients
with one
or more
defective nef
the challenges
of the coming
year.
The
research
team
made
their
observations
Researchers,
Drthe
Natalia Artemenko
and Dr
package to of
improve
automate
the export
a smartand
economy
will depend
on like-minded
Natalia V. Artemenko, Matthew P. Campbell, and Pauline
responsible for
of
Ireland
industry
research
partnership
term,death
nonprogressor
(LTNP)
patients
do
not a novel
when
compared
tothis
progressors.
generation
of photoreceptors,
research
scientists.
Theaward
newly
awareness
of our research
and9 innovation
education.
initiative
and
that
of
asequences
dynamic
innovative
culture
will ifbe M. Rudd Journal
using
zebrafish
model
ofidentifying
diabetes,
of
2010,
We
hope
determine
from
pilot
Matthew
Campbell
from
theThis
National
Institute
of
data to various
filetoformats
for
subsequent
“When
weProteome
appliedResearch,
these new
drugs(4),
to pp
our IBD
collaborative
partners
opportunities
the neurons
that
send
visual
messages
to our
Reference:
Reference:
in
2004.
develop
AIDS.
This
may
reflect
differences
in
While
the
high
frequency
of
amino
acid
2037–2041
launched
PhD
in Bioinformatics
which resembles
thefor
early
stages
ofofdiabetic
Professor
Walter
Kolch
successes.
the
Dublin
Academic
Medical
Centre
integral
to
our
success.
It
will
resonate
of
Bioprocessing
Research
& programme
Training (NIBRT)
analysis.
The
modular
architecture
the
tool
model,
the
gut
was
tricked
into
it
and
realising
basic
andfrom
applied
research
Meta-analysis
to test
the
association
ofthinking
HIV-1 nefthat
amino
demand
training
within
UCD
as
well
brain.
Predominant
cone
photoreceptor
dysfunction
in
a
the
host,
viral
genetics
or
environmental
replacement
at
particular
residues
is
indicative
The
Irish
TimesBiology
award
recognises
the stellar
retinopathy
in humans.
It is
an exciting
acid being
differences
and deletions
with disease
progression.
led by Conwayand
Fellow,
Professor
Pauline
Rudd
also
the manipulation
of datacentres
from
was
of oxygen.
This activated
synergies.
This
collaboration,
initiated
through
Director
Systems
recently
attracted
80 facilitates
(DAMC)
opens
new
possibilities
for
throughout
the
scientific
process;
from
hyperglycaemic
modeldeprived
of non-proliferative
diabetic
as
from
external
academic
and
factors
that
could
potentially
be
exploited
for
of
rapid
evolvement,
permutation
testing
Ravindra Pushker,
Jean-Marc
Jacquē,
Denis
C. Shields.
innovative
performance
of Sigmoid
Pharma
in
development
for research
the group
who now hope
to the retinopathy.
Until now,
it was
unclear
if the changes
to
other
systems.
have
developed
an
open
access,
web-based
protective
pathways,
which
in Alison
turn
prevented
a SFI
supplement,
highlights
Yolanda Alvarez,
Chen,
Professor
WalterJenneth
Kolch
EU
120
non-EU
applicants
forfor
up the
to 15 data management
the and
treatment
of of
the
disease.
showed
residues
with
more
replacements
Journal of Virology,
Apr
2010 p3644-3653
industry
willto
dictate
of
harnessing
Conway’s
research
discovery
translation
in partnership
their
application
research
and of
development.
further extend
their that
research
andstand-alone
establish
adelivery
vessels and
occurred
independently
Reynolds,the
Nore
Waghorne,
O’Connor,
Breandan
interface
thatneurons
facilitates
extraction,
querying
death
of theJohn
cellsJ.that
line the
potential
that
innovative
indigenous
companies
than
expected
were
not
statistically
significant.
The
NIBRT these
team
are
now working
to integrate
advanced
modules
inclusion within
Director,
UCD&Conway
Institute
studentships.
The
company
developed
two
drug
model
stage
diabetic
disease.
one sharing
other and
type
ofhas
retinal
neuronhave
isin new
with
industry.
Kennedy. gastrointestinal
Disease
Models
Mechanisms
(2010)Professor
and
of which
HPLC-glycan
data
generated
tract,”
explained
working
with
academia
can or
realise.”
Studies
in model
organisms
shown
that of late
GlycoExtractor with the EUROCarbDB
technologies,
and virus
SmPill™,
which
high throughput
processes.
Taylor. “Our pre-clinical trial data can now
infection
with LEDDS™
nef-deficient
shows
an not
The researchers conclude that current data
framework
to provide
a comprehensive
high-Pharma has
Taylor’s
collaboration
with Sigmoid
only
enhance
the solubility
andand
permeability
of
inform the next phase Sigmoid Pharma product
provides no evidence that individual residues
attenuated
course
of infection
some
Glycosylation isthe
the
most
and
throughput certainly
HPLC data
analysis
platform
for metrics with
been
successful
by these
drug
butcommon
can deliver
it to targeted locations
development pipeline”.
structurally diverse
and annotation
experimental
co-authoredofpublications
to date in two of
in thepost-translational
gastrointestinal tract, including thethe storagethree
modification ofcolon.
proteins. More than half of all
data. The integration
next generation
In addition to the product that is currently in
the highestofranking
scientific journals in the
GlycoExtractor advances glycan data manipulation
Zebrafish model gives insights into diabetic blindness
Success in EU FP7 call
Bioinformatic analysis of HIV progression studies
Director’s
Message
Zebrafish
model gives
insights into diabetic blindness
Conway
collaborator
scoops
Irish Times Innovation Award
GlycoExtractor
advances
glycan data
manipulation
Director’s
Message
UCD CONWAY INSTITUTE OF BIOMOLECULAR & BIOMEDICAL RESEARCH
May 2010.qxd:Layout 1 copy
07/05/2010
13:12
Page 3
Conway collaborator
Times
Innovation Award
Mismanagement
of cellularscoops
waste Irish
linked
to Alzheimer’s
Conway collaborator scoops Irish Times Innovation Award
Conway
collaborator
scoops research
Irish Times Innovation Award
2010 Festival
medal
for signalling
Irish biopharmaceutical development
company, Sigmoid Pharma recently scooped
IrishMarc
biopharmaceutical
the
overall
Innovationreceived
ofdevelopment
the Year
award
at
Dr
Birtwistle
the
2010
company,
Sigmoid
Pharma
recently
scooped
the
inaugural
Irish
Times
All-Island
UCD
Conway
Festival
of
Research
&
the overall Awards.
Innovation
thesponsored
Year award
at
Innovation
Theoflife-science
SME,
Innovation
gold medal,
by
the inaugural
Irish
Times All-Island
founded
by UCD
pharmacology
graduate, Dr
Roche,
for
his
research
to decipher
Innovation
Awards.
The life-science
SME,
Ivan
Coulter,
has actively
collaborated
the
mechanism
cells use
tograduate,
turn onwith
founded Fellow,
by UCD Professor
pharmacology
Dr
Conway
Cormac
Taylor
and
biological
decisions.
As part
of
Ivan off
Coulter,
has actively
collaborated
with
since
being
granted
a
Science
Foundation
this
prize,
MarcProfessor
is selected
as the
UCD
Conway
Fellow,
Cormac
Taylor
Ireland
industry
research
partnership
award
representative
forathe
2010Foundation
Roche
since being granted
Science
in
2004.
Researcher
of the
Yearpartnership
competition.
Ireland industry
research
award
The
Irish Times award recognises the stellar
in 2004.
innovative
performance
of Sigmoid
Pharma in
A
postdoctoral
researcher
in Systems
The
Irish Times award
recognises
the stellar
their
application
ofDr
research
and was
development.
Biology
Ireland,
Birtwistle
innovative
performance
of Sigmoid
Pharma in
initially
shortlisted
from over
85
The
hasofdeveloped
twodevelopment.
newConway
drug
theircompany
application
research
and
scientists
to
present
his
work
at
the
technologies,
LEDDS™
and
SmPill™,
The company has developed two new which
drug not
moderated
sessions
held
during
only
enhanceposter
the
solubility
permeability
of
technologies,
LEDDS™
and and
SmPill™,
which not
the
10th
annual
UCD Conway
Festival
the
but
can
it toand
targeted
locations
onlydrug
enhance
the deliver
solubility
permeability
of
of
Research
& Innovation
on
Thursday,
in
gastrointestinal
tract,
the 13:12
thethe
drug
but can
deliver
it07/05/2010
toincluding
targeted locations
May 2010.qxd:Layout
1 copy
September
16th
in
the
Institute.
colon.
in the gastrointestinal tract, including the
colon.
The
Sigmoid Pharma-Taylor
He impressed
the judgingcollaboration
committee is
with
the description
of hisof
work
facilitating
thePharma-Taylor
development
a newthat is
The Sigmoid
collaboration
uses
a systems
biology
approach
facilitating
the
development
oftreatment
a new toof
therapeutic
approach
for the
understand
how
cancer
cells
therapeutic approach
for the
treatment
of
inflammatory
bowelbreast
disease
(IBD)
by bringing
listen
tothe
two
different
signals.
inflammatory
bowel
disease
(IBD)One
by
together
research
methodology
ofbringing
the
signal
causes
these
cells
to grow,of the
together
the research
Taylor
group
with
the methodology
proprietary
whereas
thewith
other
these
cells to
Taylor group
thecauses
proprietary
liquid/emulsion
drug
delivery
system,
differentiate.
These
signals
activate
or
liquid/emulsion
drug by
delivery
system,
LEDDS®,
developed
Sigmoid
Pharma.
inactive
potential,
LEDDS®,subsequent
developed bysignalling
Sigmoid Pharma.
which whenon
perturbed
faulty have
Commenting
the award,orProfessor
Taylor
Commenting
theinaward,
Professor
been
implicated
theforprogression
of his
said,
“We
are on
delighted
Dr
Coulter Taylor
and
said, “We are
delighted
for Dr Coulter and his
numerous
types
cancer.
team
and indeed
it of
reflects
well on our
team and indeed it reflects well on our
partnership. A key driver of successful
partnership. A key driver of successful
scientific research in 2010 is meaningful
scientific research in 2010 is meaningful
interaction
with industry
industry that
that
interaction of
of academia
academia with
results in both academic outputs and the
application of research toward clinical product
results
in both
academic
outputs
and the
development
with
indigenous
companies.”
The
cells
in our
bodies
continually
listen
application
toward
clinical product
for
signals of
in research
their local
environment
Commenting with
on the
Taylor collaboration,
development
indigenous
companies.”
and
then make
appropriate
decisions Dr
Coulter
said,body
“Thefunctionality.
collaboration with
the Taylor
for
proper
A major
Commenting
on the
Taylor collaboration,
Dr
laboratory clearly
demonstrates
the research
potential
challenge
in
current
biomedical
Coulter
said,
“The collaboration
with the Taylor
that
can
be
realised
through
focused
is
to understand
the languagethe
ofpotential
this
laboratory
clearly
demonstrates
applicationin
ofterms
basic
research.
The development
listening
of
the chemical
that
can
be
realised
through
focused
of a smart occurring
economy will
depend
like-minded
reactions
within
theon
cell.
application
basic research.
The opportunities
development
collaborative
partners
identifying
Central
to of
this
systems
biology
approach
of a smart economy will depend on like-minded
and
realising
basic andunderstanding
applied researchinto
is
casting
biological
partners identifying opportunities
acollaborative
mathematical
formalism initiated
that allows
synergies.
This collaboration,
through
and realising basic and applied research
the
of computers
andhighlights
maths tothe
a SFIuse
research
supplement,
synergies.
This
collaboration,
initiated
through
understand
the system
works.
that how
innovative
indigenous
companies
apotential
SFI research
supplement,
highlights
the
working
with
academia
can
realise.”
potential that innovative indigenous companies
Dr Viviana Marzaioli, Dr Sandra Malynn,
working
with academiawith
canSigmoid
realise.”Pharma has
Taylor’s collaboration
Melissa Morine, Karen Harford, Lisa Shine
certainly
beenAhmed
successful
by
these
metrics
and
Tauseef
received
category
Taylor’s
collaboration
with
Sigmoid
Pharmawith
has
three
co-authored
publications
to
date
in two
of
prizes
for
delivering
concise
overviews
certainly
been
successful
by
these
metrics
with
Page 3
of
work
in the
themedjournals
moderated
thetheir
highest
ranking
scientific
three
co-authored
publications
to
date in
in the
two of
poster
sessions.
field,highest
Gastroenterology
and Proceeding
the
ranking scientific
journals inof
thethe
National
Academy of Sciences,
as well as
field,
Gastroenterology
and Proceeding
of the
Conference
heard
keynote
National
Academy
of Sciences,
as
well
as the
generation
ofdelegates
proprietary
innovative
products
lectures
from
Professor
Rosemary
generation
of proprietary
innovative
and the creation
of high-skilled
jobs.products
O’Connor,
University
Collegejobs.
Cork on
and the creation
of high-skilled
Morepotential
than 15,000
people in Ireland
and
the
of signalling
regulators
More
than
15,000
in Ireland
andwith the
millions
of therapeutics
people people
worldwide
are
living
as
cancer
and
Professor
millions
of
people
worldwide
living with the
Michael
White,
University
oftherapeutic
Liverpool,
symptoms
IBD today.
Currentare
symptoms
today.
Current
therapeutic
spoke
biology
approaches
optionsabout
for IBD
thissystems
chronic
debilitating
disease are
options
this
debilitating
disease
are
that
arefor
useful
to
study
cell signalling.
very limited
withchronic
surgery
often
being
the only
very
often
beingcurrently
the only
viablelimited
option.with
Thesurgery
Sigmoid
product,
viable
option.
The Aebersold,
Sigmoid
currently
Professor
Ruedi
ETH Zurich,
in a phase
II clinical
study, product,
uniquely
enables
in a phase the
II clinical study,
uniquely
enables
delivered
lecture
of the
oral delivery ofplenary
a powerful
drug without
oral delivery of a powerful drug without
causing systemic side-effects.
causing systemic side-effects.
Under normal
normal conditions,
conditions, the
the gastrointestinal
gastrointestinal
Under
tract is lined with cells that block the contents
of the gut from leaking into the intestine. In an
tract
is lined
with
cells that
block
the
IBD
patient,
barrier
ishow
broken
andcontents
the
Festival
andthis
described
proteomic
of
the gutof
from
leaking
intestine.
In an
contents
thecan
gut generate
leakinto
out the
into
surrounding
experiments
complete,
IBD
patient,
thisand
barrier
is in
broken
and
areas.
The research
team
UCD Conway
used
reproducible
quantitative
datathesets
contents
ofideally
the gut
leak
out
surrounding
areof
suited
tointo
support
athat
model
IBD
and,
by applying
a newthe
class of
areas.
The
research
team in UCD
Conwaywere
used
generation
of
models
in
drugs
known
asmathematical
hydroxylase
inhibitors,
aable
model
ofbiology
IBD completely
and,research.
by applying
systems
to almost
reversea new
the class of
drugs
known
symptoms
of as
thehydroxylase
disease. inhibitors, were
able
almost
completely
reverse the
Theto10th
annual
UCD Conway
Festival of
“When
we of
applied
these new
to our IBD
symptoms
disease.
Research
& the
Innovation
wasdrugs
sponsored
by
model,
the gut&was
tricked into thinking that it
BioSciences
Roche.
“When we applied these new drugs to our IBD
was being deprived of oxygen. This activated
model, the gut was tricked into thinking that it
protective pathways, which in turn prevented
was being deprived of oxygen. This activated
the
death of
the cellswhich
that line
the prevented
protective
pathways,
in turn
gastrointestinal
explained
the
death of the tract,”
cells that
line theProfessor
Taylor. “Our pre-clinical
trial dataProfessor
can now
gastrointestinal
tract,” explained
inform “Our
the next
phase Sigmoid
product
Taylor.
pre-clinical
trial dataPharma
can now
development
pipeline”.
inform
the next
phase Sigmoid Pharma product
development pipeline”.
In addition to the product that is currently in
phase
II clinical
Pharma in
is
In
addition
to thestudies,
productSigmoid
that is currently
developing
a LEDDS™-enabled
phase
II clinical
studies, Sigmoidformulation
Pharma is of
developing
a LEDDS™-enabled
formulation of
the hydroxylase
inhibitor
the
hydroxylase inhibitor(DMOG) to bring about
dimethyloxaloylglycine
dimethyloxaloylglycine
(DMOG)
to bring
about
effective, safe and targeted
delivery
of this
effective,
and targeted
potential safe
therapeutic
agent.delivery of this
potential therapeutic agent.
Prof. Walter Kolch, Director, UCD Conway; Simon
Thorpe, Roche Diagnostics Ltd; Dr Marc Birtwistle,
winner 2010 UCD Conway Festival gold medal; Dr
Oliver Blacque, Chair, Conway Lecture & Seminar
Series committee.
Conway
collaborator age
scoops Irish Times Innovation Award
Science in
the information
Irish global
biopharmaceutical
development
The
scientific community
In the
company, Sigmoid
recently
scooped
information
age isPharma
not only
concerned
the overall
Innovation
of thediscovery
Year award
with
advancing
scientific
butat
the inaugural
Irish
Times
All-Island of
with
improving
the
methodology
Innovation
Awards.
The life-science
SME,
the
scientific
process.
There are two
recent
of Conway researchers
foundedexamples
by UCD pharmacology
graduate, Dr
Ivan Coulter,this
has
actively
collaborated
with
influencing
led by
Meta-analysis
by work.
UCD researchers
results
in bothproposal,
academic outputs
The
MIAPAR
which and the
application
of research
toward
was
outlined
earlier this
yearclinical product
development
with indigenous
companies.”
in
a communication
to Nature
Biotechnology,
allows
subsequent
users
Commenting on the Taylor collaboration, Dr
to
make a fully informed evaluation of
Coulter said, “The collaboration with the Taylor
the validity of conclusions drawn from
laboratory clearly demonstrates the potential
use
of ainparticular
product.
studies
humans have
shown
shown that
that non
non
since
being
granted
a Science
Foundation
Conway
postdoctoral
Dr Niall
determined
that
there
isresearcher,
no clear
evidence
Ireland
industry
research
partnership
award
Haslam
from the
Complex
Adaptive
that particular
particular
defective
viral
sequences
in
that
defective
viral &
sequences
in
in
2004.
Systems
Laboratory
(CASL)
worked
the
HIV-1
nef
gene
or
certain
regions
of
the
the HIV-1 nef gene or certain regions ofon
the
the
minimum
information
about
protein
play
significant
role
The
Irishplay
Times
award recognises
theprotein
stellar
protein
aa significant
role in
in disease
disease
affinity
reagent
(MIAPAR)
proposal;
an in
progression.
innovative
performance
of Sigmoid
Pharma
progression.
international
to define
a checklist
their applicationeffort
of research
and development.
HIV-infected information
patients can
categorised
on
of
the
HIV-infected
can be
bedescribing
categorised
on
Therequired
companypatients
has developed
two new drug
the basis of of
theanumber
ofbinding
years it reagent
takes for
properties
protein
the basis of the
numberand
of years
it takes
for not
technologies,
LEDDS™
SmPill™,
which
them every
to progress
to AIDS. Some
patients
with
known
partner.
only
the solubility
and
permeability
themenhance
to progress
to binding
AIDS. Some
patients of
application of basic research. The development
Dr
Niall Haslam
that “by
deletions
the nefexplains
gene.depend
of
a smartineconomy
on like-minded
providing
MIAPAR will
compliment
collaborative
partners
identifying
opportunities
However,
much
of
the
research
in
documents
for
the
affinity
reagents
However, much of the research in the
the area
area to
to
and
realising
basic and
applied
research
date
been
observational
used
in experiments
with
theor
date has
has
been based
based on
onalong
observational
or case
case
synergies.
This
collaboration,
initiated
through
studies
than
systematic
scientific
communication
the research,
studies rather
rather
than rigorous,
rigorous,of
systematic
ascientific
SFI research
highlights
the
evaluation.
This
work
by
scientists
cansupplement,
support
the
efficient
use of
scientific
evaluation.
This
work
by doctoral
doctoral
potential
that
innovative
indigenous
companies
candidate
Ravindra
Pushker
set
out
to
the
products
for
the
benefit
of
the
entire
candidate
Ravindra
Pushker
set
out
to
working
with
can realise.”
determine
in academia
a substantially
larger sample set
scientific
determinecommunity.”
in a substantially larger sample set
tract
lined with cellsinthat
block the
contents
tasksis encountered
a typical
protein
of
the gut fromproject
leaking while
into the
intestine. In an
engineering
integrating
IBD
this barrier
broken and the
datapatient,
deposition
in theis process.
contents of the gut leak out into surrounding
areas.
The research
teambenefits
in UCD Conway
Commenting
on the
of PEAT,used
aDr
model
of IBD
and,“PEAT
by applying
a new class
Nielsen
said,
incentivises
dataof
drugs
ascritical
hydroxylase
were
storage
byare
integrating
theinhibitors,
processthe
with
of
nef
in
rate
of HIV
HIVknown
nef
are
critical
in determining
determining
the
rate
able
to
almost
completely
reverseapplication.
the
the
analysis
tools
in a single
of
progression.
Professor
Denis
of disease
disease
progression.
Professor
Denis
symptoms
of the that
disease.
Through
widespread
use of for
PEAT,
we canof
Shields
Shields believes
believes
that searches
searches
for modifiers
modifiers
of
Bioinformatic analysis of HIV progression studies
Conway Fellow,
Fellow, Professor
Professor Cormac
Taylor has
Denis Shields
Conway
maintain stable CD4 lymphocyte counts and
the
drug but
canCD4
deliver
it to targeted
locations
maintain
stable
lymphocyte
counts
and
do not go on
to develop
AIDS even
after more
Currently,
there
are tract,
multiple
sources
in
the
gastrointestinal
including
the more
do
not
go
on
to
develop
AIDS
even
after
than
10 years of on
infection.
of
information
affinity reagents
colon.
than 10 years of infection.
in
existence including commercial
Scientists are curious as to why these longThe Sigmoid
Pharma-Taylor
collaboration
is
catalogues,
experimental
results
Scientists
curious as
to why
these longterm, non-are
progressor
(LTNP)
patients
not
facilitating
the
development
of patients
a new
published
in scientific
journals
and do
term,
nonprogressor
(LTNP)
do
develop AIDS. This may reflect differencesnot
in
web
portals
that
centralise
affinity
therapeutic
approach
for
the
treatment
of
develop
This mayorreflect
differences in
the host,AIDS.
viral genetics
environmental
reagent
properties
from
many
sources.
inflammatory
bowel
disease
(IBD)
by
bringing
the
host,that
viral
genetics
or environmental
factors
could
potentially
be exploited for
However,
available
information
together thethe
research
methodology
of the
factors
that could
potentially
be exploited for
the
treatment
of
the
disease.
may
incomplete,
inaccessible,
Taylorbe
group
with the proprietary
the
treatment
of
the
disease.
unsubstantiated
ordelivery
may even
appear
liquid/emulsion
system,
Studies in modeldrug
organisms
have
shown that
contradictory
due
to
of precision
in
LEDDS®,
developed
by lack
Sigmoid
Pharma.
infectioninwith
nef-deficient
virus
shows
Studies
model
organisms
have
shownanthat
target
orwith
sample
descriptions.
attenuated
course
of
infection
and
somean
infection
nef-deficient
virus
shows
Commenting on the award, Professor Taylor
attenuated
course
of infection
and some
said,
“We are
delighted
for Dr Coulter
and his
team and indeed it reflects well on our
partnership. A key driver of successful
scientific research in 2010 is meaningful
that can be realised through focused
progression was associated with
with gross
gross
if any association
exists
Taylor’s
collaboration
withbetween
Sigmoiddisease
Pharma has
if any association
exists
between
disease
progression
and
particular
amino
acid
Conway
Fellow,
Dr JensbyErik
Nielsen
certainly
been
successful
these
metrics with
progression
and
particular
amino
acid
differences
or deletions
withinato
the
nef in
gene.
and
his
team
have
created
protein
three
co-authored
publications
date
two of
differences
or
deletions
within
the
nef
gene.
engineering
analysis
tool (PEAT)
that
the
highest
ranking
scientific
journals
in
the of
On
a
per
patient
basis,
there
was
no
excess
facilitates
the analysis
ofProceeding
experimental
On a Gastroenterology
per
patient
basis,
there
wasdefective
no excess
field,
and
of the
LTNP
patients
with
or
more
nefof
data
generated
inofone
the
course
a as the
LTNP
patients
with
one
or
more
defective
nef
National
Academy
Sciences,
asof
well
sequencesproject
when compared
toensuring
progressors.
research
as
well
as
that
generation
of
proprietary
innovative
products
sequences
when
compared
to
progressors.
While
the
high
frequency
of
amino
acid
this
valuable
data
is available
foracid
future
and
the
creation
of high-skilled
jobs.
While
the
high
of amino
replacement
at frequency
particular
residues
is the
indicative
use.
The team
recently described
replacement
at
particular
residues
is
indicative
of rapid
evolvement,
permutation
testing
application
in thepeople
journal,
Nucleic
More
than
15,000
in Ireland
andAcids
of
rapid
evolvement,
permutation
testing
showed
that
residues
with
more
replacements
Research.
millions of people worldwide are living with the
showed
that
residues
with
more
replacements
than
expected
were
statistically
significant.
symptoms
IBD
today.not
Current
therapeutic
than expected
were
not
statisticallydisease
significant.
options
for
this
chronic
debilitating
PEAT
is
not
simply
a
laboratory
The researchers conclude that current data are
very
limited
with
surgery
often
being
the
only
information
management
system,
but
provides
no evidence
that individual
residues
The researchers
conclude
that current
data
has
been
designed
to
address
specific
viable
option.
The
Sigmoid
product,
currently
provides no evidence that individual residues
in a phase II clinical study, uniquely enables
oral delivery of a powerful drug without
causing systemic side-effects.
create
and share
high quality
datasets
progression
rates
should
now
focus
progression
ratesthese
should
now
focus
on
other
“When
we applied
new
drugs
toon
ourother
IBD
on
the
connections
between
protein
host
and
viral
factors.
“Systematic
evaluation
host and
factors.
“Systematic
evaluation
model,
the viral
gut was
tricked
into thinking
that it
sequence,
structure
andbyfunction”.
of
large
quantities
of
data
bioinformatics
of large
by bioinformatics
was
beingquantities
deprived of data
oxygen.
This activated
can
as
in
can be
be just
just
as important
important
ininrefuting
refuting
protective
pathways,
which
turn prevented
The
work on
MIAPAR
wasinsupported
hypotheses
that
are
the
the
death of the
that
lineinthe
hypotheses
thatcells
are current
current
the literature,
literature, as
as
through
funding
received
from
European
itit is
in
discovering
unknown
patterns”,
he said.
gastrointestinal
tract,”
explained
Professor
is
in
discovering
unknown
patterns”,
Union Framework Programmes (EU he
FP)said.
Taylor.
“Our pre-clinical
trialthrough
data can
now
funded
Science
6This
& 7.research
PEAT iswas
being
funded
through
This
research
was
funded
through
Science
inform
the next
phase
Sigmoid
Pharma
product
Foundation
Ireland
and
University
College
awards
from
Science
Ireland,
Foundation
Ireland
and Foundation
University College
development
pipeline”.
Dublin.
the
Health
Research
Board,
Higher
Dublin.
Education
and
UCD
Ad Astra
In
addition toAuthority
the product
thata is
currently
in
scholarship.
is available
at http://
phase II clinicalPEAT
studies,
Sigmoid Pharma
is
enzyme.ucd.ie/PEAT
developing
a LEDDS™-enabled formulation of
the
hydroxylase
inhibitor
Reference:
Reference
:
Reference: to test the association
Meta-analysis
ofto
HIV-1
nef amino
dimethyloxaloylglycine
(DMOG)
bring
Bourbeillon J et al.Minimum
information
aboutabout
acid
differences
with
disease
progression.
Meta-analysis
testdeletions
the
association
of HIV-1
nef amino
effective,
safetoand
and
targeted
delivery
of
this
aRavindra
protein Pushker,
affinity
reagent
(MIAPAR).
Nature
Jean-Marc
Denisprogression.
C. Shields.
acid differences and
deletionsJacquē,
with disease
Biotechnology
2010
Jul;28(7):650-3.
potential
therapeutic
agent.
Journal
Virology,Jean-Marc
Apr 2010 p3644-3653
RavindraofPushker,
Jacquē, Denis C. Shields.
Journal of Virology, Apr 2010 p3644-3653
Farrell D et al. Capturing, sharing and analysing
biophysical data from protein engineering and
protein characterization studies Nucl. Acids Res.
(2010) 38(20): e186 doi:10.1093/nar/gkq726
UCD
Conway researchers
believe that
Irish biopharmaceutical
development
acompany,
failure to
maintain
an efficient
flux of
Sigmoid
Pharma
recently scooped
cellular
waste
through
lysosomes
the overall
Innovation
of the
Year awardisata
risk
factor for
developing
Alzheimer’s
the inaugural
Irish
Times All-Island
disease.
findings
of their research
InnovationThe
Awards.
The life-science
SME,
were
recently
in the
Journal
founded
by UCD published
pharmacology
graduate,
Dr
of
Biological
Chemistry.
Ivan
Coulter, has
actively collaborated with
neuron
and may
underlie
the
results infunction
both academic
outputs
and the
cognitive
associated
with
Alzheimer’s
applicationloss
of research
toward
clinical
product
disease.
development with indigenous companies.”
Commenting
Taylor Research
collaboration,
Dr
a study ledonbytheHealth
BoardSuccess in EU FP7 call Infunded
Coulter said,
“The fellow,
collaboration
with Boland,
the Taylor
research
Dr. Barry
laboratory
demonstrates
the potential
the clearly
co-supervision
of Conway
Success
in EU FP7 call under
that can Prof.
be realised
through
focused
Fellow,
Dominic
Walsh
and Prof.
Conway Fellow, Professor Cormac Taylor
disease (CKD)
and improve
treatment,
Conway researchers
by Dr.cells
Tara strikes
application
of basic
research.
The
development
Frances
Platt
(University
ofpatient
Oxford),
AVs
The
statealed
of
living
sincemetabolic
being granted
Science
Foundation
of
a
smart
economy
will
depend
on
like-minded
McMorrow
and
Professor
Michael
Ryan
have
with
particular
focus
on
CKD
arising
from
were
shown
to
accumulate
inside
neurons
aIreland
fine balance
between
growth
and
industry research partnership award
disease
(CKD)
and cannot
improve
patient
treatment,
Conway
researchers
led
by Dr.this
Tara
collaborative
identifying
opportunities
diabetes
and partners
hypertension.
The multiwhen
lysosomes
digest
AVs
and
successfully
secured
€485,500
inequilibrium
funding as
degradation.
Cells maintain
in
2004.
and
realising
basic
applied
McMorrow
and making
Professor
Michael
Ryan have
with
particular
focus
on
CKD arising
when
AVs are
not and
delivered
toresearch
lysosomes.
disciplinary
research
consortium
hasfrom
25
partconstantly
of an overall
awardnew,
to
the
Systems
by
and
removing
The Irish Times award recognises the stellar
synergies.
This
collaboration,
initiated
through
diabetes
hypertension.
multi-partners)
successfully
€485,500
in
fundingtheir
as
old,
parts
ofsecured
themselves.
TheyKidney
package
partnersand
(16
universities,
9The
industry
Biology
towards
Novel
Chronic
innovative
performance
of
Sigmoid
Pharma in
a SFIteam
research
supplement,
highlights
the
disciplinary
research
consortium
has
25
part
ofwaste
anDiagnosis
overall
award
tothat
the Systems
own
into
vesicles
are
degraded
The
used
this
model
to
investigate
from
15
countries
and
the
project
is
due
to run
Disease
and
Treatment
(SysKid)
their application of research and development.
potential(16
that
innovative
indigenous
partners
universities,
9 industry
partners)
Biology
towards
Novel
ChronicasKidney
by
acidic
organelles
lysosomes.
whether
a protein
associated
withcompanies
plaque
for five years.
consortium
theknown
European
Union
FP7
The
companyunder
has developed
two new
drug
working
with
academia
canproject
realise.”
This
process
cellular
rubbish disposal
from
15 countries
and the
is due
to run
formation
disease,
amyloid
Disease
Diagnosis
and Treatment
(SysKid)
May 2010.qxd:Layout
1of
copy
07/05/2010
Page
3 in Alzheimer’s
programme.
technologies,
LEDDS™
and
SmPill™, which 13:12
not
involves
cells
eating
parts
of themselves
precursor
proteinteam,
(APP),
is delivered
Thefive
UCD
Conway
postdoctoral
for
years.
consortium
under
the European
Union FP7
Taylor’s
collaboration
withincluding
Sigmoid
Pharma has
only enhance the solubility and permeability of
and
is known as autophagy
(self-eating).
to
lysosomes
byCraig
AVs.Slattery
They
found
programme.
researchers
Dr.successful
and metrics
Dr.that
Natalia
Syskid
established
to
certainly
by these
with
the
drug(www.SysKid.eu)
but can deliver itwas
targeted
locations
The
UCD been
Conway
including
postdoctoral
During
autophagy,
wasteto
material
is
fragments
APPteam,
areculture
degraded
by
Martin,
willof
utilise
cell
and
animal
further
our
understanding
of
chronic
kidney
three
co-authored
publications
to
date
in
two
in
the
gastrointestinal
tract,
including
the
researchers
Dr.
Slattery and
Natalia of
Syskid
(www.SysKid.eu)
was established
to
digested
into basic building
blocks (sugars,
lysosomes
butCraig
notscientific
delivered
toDr.
lysosomes
the highest
rankingcell
journals
in the
colon. our
Martin,
will
utilise
culture
and indicated
animal
further
understanding
of chronic
kidney
amino
acids
and lipids) that
can then
be
by
AVs.
Instead,
their
research
field, Gastroenterology and Proceeding of the
reused
to
make
new
parts
of
the
cell.
that
amyloidogenic APP fragments are
The Sigmoid Pharma-Taylor collaboration is
National Academy of Sciences, as well as the
Neurons
for manyofdecades
delivered to lysosomes from the plasma
facilitatingsurvive
the development
a new in
generation of proprietary innovative products
the
humanapproach
brain andforhave
exceptionally
membrane via endocytosis.
therapeutic
the treatment
of
and the creation of high-skilled jobs.
efficient
autophagy.
However,
inflammatory
bowel disease
(IBD)in
bybrains
bringing
of
people
affected
by
Alzheimer’s
disease,
Commenting
on the
study,
Dr. Boland
More than 15,000
people
in Ireland
and
together the research methodology of the
the
ability
ofwith
neurons
to clear out
cellular
said,
highlights
the important
role the
cells,“This
tissues
and fluids.
Glycomics
needs
the proprietary
supporting
framework
millions
of people
worldwide
are living with
Taylor
group
the
waste
is compromised.
This
leads
toand
an
that
lysosomes
play
in removing
cellular
of
extensive,
well-curated
databases
symptoms
IBD
today.
Current
therapeutic
cells,
tissues
and
fluids.
Glycomics
needs
the delivery
supporting
framework
liquid/emulsion
drug
system,
Commercial neurons,
packages that support
HPLC
accumulation
of waste
containing
vesicles
waste
clarifying
theare
flexible
analytical
tools.
Currently,
this
optionsfrom
for this chronicwhile
debilitating
disease
of
extensive,
well-curated
databases
andfield
LEDDS®,
developed
by Sigmoid
Pharma.
instruments
cannot facilitate
the
extraction
of
Commercial
packages
that
support
HPLC
or
autophagic
vacuoles
(AVs) thatthis
impair
route
APP fragments
take
on
their
delivery
very limited
with surgery
often
being
the
only
of study
lacks the
established,
flexible
analytical
tools.
Currently,
field
to lysosomes.
We
believe
that the
therapies
tract
is lined with
cells
that block
contents
aimed
at from
improving
waste In an
of
the gut
leakinglysosomal
into the intestine.
disposal
could
alleviate
IBD
patient,
this prevent
barrier isand
broken
and thethe
neuronalofdysfunction
associated
with
contents
the gut leak out
into surrounding
Alzheimer’s
disease.”
areas.
The research
team in UCD Conway used
a model of IBD and, by applying a new class of
This work
was
grants from
drugs
known
as supported
hydroxylaseby
inhibitors,
were
the Health
Research
Board
of Ireland,
able
to almost
completely
reverse
the
models
to
identify
processes
involved
in
early
the Wellcome
Science Foundation
symptoms
of theTrust,
disease.
CKD progression
investigate
Ireland
and UCDand
Seed
Fund. novel
models
to identify
processes
“When
we
applied
these new
drugs
toinour
IBD
strategies
for preventing
andinvolved
slowing
theearly
Reference
CKD
progression
andtricked
investigate
novel
model,
gutof
was
into
thinking
that
it
progression
the
disease.
These
studies
will
Boland
B,the
Smith
DA,
Mooney
D, Jung
SS,
Walsh
DM,
Platt
strategies
for
preventing
slowing
the in
was
beingMacroautophagy
deprived
of oxygen.
This
activated
be(2010)
integrated
with clinical
epidemiological
FM
isand
notand
directly
involved
progression
ofofthe
These
studies
will
protective
pathways,
which
in turn
prevented
the
metabolism
amyloid
precursor
protein.
Journal
of
studies
across
thedisease.
consortium
using
systems
Biological
285:37415-37426.
be
integrated
withcells
clinical
epidemiological
the
deathChemistry
of the
thatinand
line
theto develop new
biology
methodologies
order
studies
across
the
consortium
using
systemsto
gastrointestinal
tract,”
explained
Professor
diagnostic
strategies
and
treatment
options
biology
methodologies
in
order
to
develop
Taylor.
“Our
pre-clinical
trial
data
can
now new
prevent CKD development. Email
diagnostic
treatment
options
inform
the strategies
next phaseand
Sigmoid
Pharma
[email protected]
for
details
of a product
PhDto
prevent
CKD development.
Email
development
pipeline”.
position currently
available.
[email protected] for details of a PhD
In addition
to the product
position
currently
available.that is currently in
phase II clinical studies, Sigmoid Pharma is
developing a LEDDS™-enabled formulation of
the hydroxylase inhibitor
dimethyloxaloylglycine (DMOG) to bring about
effective, safe and targeted delivery of this
potential therapeutic agent.
EUROCarbDB, a research infrastructure design
study funded abyresearch
the EU 6th
Frameworkdesign
EUROCarbDB,
infrastructure
Programme.
Prospective
users
can access the
study
funded
by
the
EU
6th
Framework
Cortical neuron showing the co-localisation of autophagic
GlycoExtractor
toolwith
onlysosomes
Programme.
Prospective
users can
access
vacuoles
(LC3, green)
(LAMP1,
red)the
http://glycobase.nibrt.ie:8080/DemoGlycoExtra
GlycoExtractor
tool on
http://glycobase.nibrt.ie:8080/DemoGlycoExtra
ctor/mainPage.
ctor/mainPage.
Reference
GlycoExtractor advances glycan data manipulation
GlycoExtractor advances glycan data manipulation
large quantities
data.
In product,
antheeffort
to alleviate
instruments
facilitate
extraction
of
Commenting
the
award,
Professor
viable
option.cannot
TheofSigmoid
currently
comprehensive
centralised
data Taylor
of
study lackson
theand
established,
this
bottleneck
within
high-throughput
large
quantities
of
data.
In
an
effort
to
alleviate
said,
“We
are
delighted
for
Dr
Coulter
and
his
in a phase II clinical study, uniquely enables
comprehensive
and centralised
data
collections, standards
and information
this
bottleneck
team and indeed
it reflects
well
on our
glycomic
projects,
thehigh-throughput
NIBRT
have
oral
delivery
ofwithin
a powerful
drugteam
without
collections,
standards
and
information
reporting protocols
that
exist
within
glycomic
projects,
the NIBRT
teaminterfaces
have
partnership.
A key driver
of successful
developed
a
web-based
tool
that
causing
systemic
side-effects.
reporting
protocols
that
exist
within
genomics and proteomics.
developed
a web-based
tool that interfaces
scientific research
in 2010 is meaningful
with the Waters
chromatography
software
genomics
and proteomics.
Under
conditions,
the gastrointestinal
thenormal
Waters
chromatography
software
interaction of 1
academia
industry
that
package
to
improve
and automate
the export
Researchers,
Dr
Natalia with
Artemenko
and
Dr 13:12 with
May 2010.qxd:Layout
copy
07/05/2010
Page
3
results
intoboth
academic
outputs and
the
IrishElton
biopharmaceutical
development
Dr.
Rexhepaj
received
theand
European
(IHC) annotation
andautomate
facilitate
the
Researchers,
Dr Natalia
Dr
package
improve
and
export
of data to
various
file
formats for the
subsequent
Matthew Campbell
fromArtemenko
the National
Institute
application
ofof
research
toward
clinical
product
company,
Pharma
recentlyInstitute
scooped
Society
ofSigmoid
Toxicologic
Pathology
(ESTP)
translation
biomarker
discovery
to
Matthew
Campbell
from
the
National
of
data to various
file formats
for
subsequent
of
Bioprocessing
Research
&
Training
(NIBRT)
analysis.
The
modular
architecture
of
the tool
development
with indigenous
companies.”
the
overall
Innovation
of the
Year award
at
thesis
award
in
Budapest,
Hungary
on
clinical
implementation.
of
Bioprocessing
Research
&
Training
(NIBRT)
analysis.
The
modular
architecture
of
the
tool
led
by
ConwayIrish
Fellow,
Professor
Pauline Rudd
also facilitates the manipulation of data from
theby
inaugural
Times
All-Island
led
Conway30th
Fellow,
Professor
Pauline
Rudd
also
facilitates
thethe
manipulation
of data from
September
2010.
This
prestigious
Commenting
on
Taylor
collaboration,
Dr
have
developed
an
open
access,
web-based
other
data
management
systems.
Innovation
Awards.
life-science
SME,
have
developed
an open
access,
web-based
other
data
management
systems.with
prize,
sponsored
byThe
Boehringer
Ingelheim
Dr. Elton
Rexhepaj,
together
withthe
Conway
Coulter
said,
“The collaboration
Taylor
interface
thatUCD
facilitates
extraction,
querying
founded
by
pharmacology
graduate,
Dr
interface
that
facilitates
querying
The NIBRT
team are
now working
to integrate
Pharma
GmbH
& Co.extraction,
KG, data
is offered
every
Fellow,
Professor
William
Gallagher
and
laboratory
clearly
demonstrates
the
and
sharing
of HPLC-glycan
generated
in
The
NIBRT
team are
now working
topotential
integrate
Ivansharing
Coulter,
actively collaborated
with
and
of has
HPLC-glycan
data
generated
in
GlycoExtractor
withthrough
the
EUROCarbDB
that
can
be
realised
focused
second
year
for
a
thesis
in
toxicological
clinician-scientist,
Dr.
Donal
Brennan
high
throughput
processes.
GlycoExtractor
with
the
EUROCarbDB
Conway
Fellow,processes.
Professor Cormac Taylor
high
throughput
framework
to basic
provide aa comprehensive
highapplication
of
Theproprietary
development
pathology.
created
IHC-MARK;
novel,
framework
to
provideresearch.
a comprehensive
highsince being granted a Science Foundation
Glycosylation
is
the
most
commonand
and
throughput
HPLCtoolkit
data
analysis
platform
for
Meta-analysis
by
UCD
researchers
led by
studies
in humans
have
shown
that
nonfor
of
a smart
economy
will
depend
on
like-minded
image
analysis
for the
assessment
Glycosylation
is the
most
common
throughput
HPLC
data
analysis
platform
Ireland industry
research
partnership award
Conway Fellow,
Professor
Denis
Shieldsanhas
progression
was
associated
gross
theIHC-based
storageand
and
annotation
experimental
structurally
diverse
post-translational
collaborative
partners
identifying
opportunities
Rexhepaj’s
doctoral
thesis
describes
of
markers.
This
technology,
structurally
post-translational
the
storage
annotation
ofofwith
experimental
in 2004. diverse
determined of
that
there isMore
no clear
deletions
in
the
nefand
gene.
data.realising
TheIHC-MARK,
integration
next
generation
modification
ofimage
proteins.
More
thanevidence
halfofofall
all
and
basic
applied
research
modification
proteins.
than
half
data.
The
integration
ofofisnext
generation
automated,
analysis
approach
termed
currently
in
The
Times
award
recognises
that Irish
particular
defective
viral
in
synergies.
This
collaboration,
initiated
through
gene
products
have
been
shown
tothe
bestellar
bioinformatic
tools
will
further
the treatment,
disease
(CKD)
and
improve
patient
Conway
researchers
led shown
by
Dr.sequences
Tara
bioinformatic
tools
will
further
the
gene
products
have
been
to
be
for
clinical
pathologists
and
biomedical
beta-testing
phase
and
provides
non-to
However,
much
of
the
research
in thea area
innovative
performance
of
Sigmoid
Pharma
in
the
HIV-1
nef
gene
or
certain
regions
of
the
a
SFI
research
supplement,
highlights
the
glycosylated.
With
manyspecific
specific
glycans
or
development
of
unified
approaches
for
McMorrow
and
Professor
Michael
Ryan
have
with
particular
focus
on
CKD
arising
from
glycosylated.
With
many
glycans
or
development
of
unified
approaches
for
date
has
been
based
on
observational
or
case
researchers
in
histopathology
laboratories
supervised
approach
to
the
discrimination
their
application
of
research
and
development.
protein playshowing
a significant
roleas
incancer
disease
potential
that
innovative
indigenous
companies
glycoforms
showing
potential
as
handlingrather
large
scalerigorous,
glycomics
datainitiatives
initiatives
glycoforms
potential
handling
large
scale
glycomics
data
diabetes
and
hypertension.
Thesystematic
multisuccessfully
€485,500
in
funding
studies
than
to
automate
immunohistochemistry
of
biomarker
protein
expression
at the
The
companysecured
has
developed
twocancer
new
drug as
progression.
working
with
academia
can
realise.”
biomarkers,
there
is
an
increasing
need
to
with
applications
in
biomarker
discovery
biomarkers,
there
isaward
an increasing
needwhich
to not
with
applications
in biomarker
disciplinary
research
consortium
has
25
part
of an overall
to the
Systems
scientific
evaluation.
This workdiscovery
by
doctoral
technologies,
LEDDS™
and
SmPill™,
develop
highthroughput,
throughput,
highly
sensitiveon
and
develop
high
highly
sensitive
and
partners
(16
universities,
industry
partners)
Biology
towards
Chronic
Kidney
HIV-infected
patients
can
be
categorised
candidate
Ravindra
Pushker
set outPharma
toby
Taylor’s
collaboration
with9 Sigmoid
only
enhance
theNovel
solubility
and
permeability
of
This
research
was
partially
supported
by has
This
research
was
partially
supported
robust
strategies
that
detail
the
glycome
robust
strategies
that
detail
the
glycome
ofof
from
15 countries
and the by
project
due to set
run
Disease
Diagnosis
and
Treatment
the drug
basis
of the
it (SysKid)
takes
for
determine
in asuccessful
substantially
larger
sample
certainly
been
theseismetrics
with
the
but
cannumber
deliver
itoftoyears
targeted
locations
them
progress
Some
patients
if any
association
exists between
disease
for
fiveco-authored
years.
consortium
under to
theAIDS.
European
Union
FP7
three
publications
to date
in two of
in
the to
gastrointestinal
tract,
including
the
maintain stable CD4 lymphocyte counts and
progression
and particular
acidin the
programme.
the
highest ranking
scientificamino
journals
colon.
More
than 500 DNA samples
from
conditions.
It academic
is frequently
accompanied
results
both
outputs
and the
Irish biopharmaceutical
development
The
UCDinConway
team, including
do not go on to develop AIDS even after more
differences
or deletions
within
thepostdoctoral
nef gene.
field,
Gastroenterology
and
Proceeding
of the
well
characterised
patients
withscooped
by
psoriasisof
vulgaris
(PsV),
aclinical
common
application
research
towardand
product
company,
Sigmoid
Pharma
recently
researchers
Dr.
Craig
Slattery
Syskid
wascollaboration
established
tois
The
Pharma-Taylor
thanSigmoid
10(www.SysKid.eu)
years
ofpsoriatic
infection.
National Academy
of Sciences,
as Dr.
wellNatalia
as the
psoriasis
and
arthritis
in
St
chronic
inflammatory
disease
that
development
with
indigenous
companies.”
the
overall
Innovation
of
the
Year
award
at
On
a
per
patient
basis,
there
was
no
excess
of
Martin,
will of
utilise
cell culture
and animal
further
our the
understanding
of of
chronic
facilitating
development
a new kidney
generation
proprietary
innovative
products
Vincent’s
University
(SVUH)
affects
the skin
and
mediated
by
T nef
the
inaugural
Irish Times
All-Island
Scientists
are
curious
as Hospital
to
why
these
longLTNP patients
with
oneis or
more defective
therapeutic
approach
for
the
treatment
of
and
the creation
of high-skilled
jobs.
Commenting
on the
Taylor collaboration,
Dr
were
analysed
as The
part
of(IBD)
two
separate
cells.
Innovation
Awards.
life-science
SME,
term, nonprogressor
(LTNP)
patients
do not
sequences when compared to progressors.
inflammatory
bowel disease
by bringing
Coulter
said,
“The
collaboration
with
the Taylor
genome-wide
association
studies
most
likely
to
die
as
a
result
of
the
raised
New
research
led
by
Conway
Fellow
Dr
founded
by
UCD
pharmacology
graduate,
Dr
develop
AIDS.
This
may
reflect
differences
in
While
the
high
frequency
of
amino
acid
More
than
15,000
people
in
Ireland
and
together
the research
methodology
of Dr
the
most likelyclearly
to die demonstrates
as a result of the
New
research
led by Conway
Fellow
laboratory
the raised
potential
(GWAS).
The
results
both
studies
glucose
inindiabetes.
Breandán
Kennedy
indicates
that
treatment
A
stronglevels
genetic
component
hadthe
Ivan
Coulter,
has
actively
collaborated
with
the host,
viral
genetics
orof
environmental
replacement
atseen
particular
residues
isPsA
indicative
millions
of
people
worldwide
arefor
living
with
Taylor
group
with
the
proprietary
glucose
levels
seen
diabetes.
Breandán
Kennedy
indicates
that
treatment
that
can
be
realised
through
focused
were
recently
published
in
Nature
previously
been
suggested
by
several
of
diabetic
blindness
shouldCormac
look
atTaylorfor
Conway
Fellow,
Professor
factors
that
could
potentially
be
exploited
of
rapid
evolvement,
permutation
testing
symptoms
IBD
today.
Current
therapeutic
liquid/emulsion
drug
delivery
system,
of diabetic blindness should look at
Dr
Kennedy
and
hisnow
teamthere
found
that
new blood
application
of
basic
The
development
Genetics.
studies
but
until
was
limited
protecting
the
neurons
responsible
for colour
since
being
granted
a Science
the treatment
the disease.
showed
thatthis
residues
with
more
replacements
Dr Kennedy
and
hisresearch.
team
found
that
new blood
options
for
chronic
debilitating
disease
are
LEDDS®,
developed
by
SigmoidFoundation
Pharma.
protecting
theofneurons
responsible
for colour
vessels
andeconomy
the
neuronal
cell components
death
diabetic
of a smart
will depend
on in
like-minded
knowledge
of
the
genetic
vision
the eye research
and not just
targetingaward
the
Irelandinindustry
partnership
than
expected
were
not
statistically
significant.
vessels
and
the
neuronal
cell
death
in
diabetic
very limited
with
surgery
often being the
only
Glycomics
needs
the
supporting
framework
cells,
tissues
and
fluids.
vision
in
the
eye
and
not
just
targeting
the
retinopathy
independently
of each
collaborativecan
partners
identifying
opportunities
Studies
in contribution
model
organisms
have
shown
that
The
Irish
to Professor
these
Commenting
on
award,
Taylor
contributing
toarise
PsA.
Theproduct,
findings
blood
vessels
as the
is
currently
the practice.
in
2004.
viable
option.can
The
Sigmoid
currently
retinopathy
arise
independently
of each
of
extensive,
and
blood
vessels
as
is currently
practice.
other.
In addition,
they
that cone
and
basic
andidentified
applied
research
infection
with
nef-deficient
virus
shows
an
The realising
researchers
conclude
that identified
current
dataa
international
collaborative
projects
was
said,
“We
arewell-curated
delighted
for databases
Dr the
Coulter
and
his
outlined
in
this
publication
Commercial
packages
that
support
HPLC
in
a
phase
II
clinical
study,
uniquely
enables
other.
In
addition,
they
identified
that
cone
The
Irish
Times
award
recognises
the
stellar
flexible
analytical
tools.
Currently,
this
field
photoreceptor
neurons,
those
involved
in 6
Nearly
2.5
million
people
worldwide
are
blind
synergies.
This
collaboration,
initiated
through
provides
no
evidence
that
individual
residues
attenuated
course
of
infection
and
some
coordinated
by
clinician
scientists
in
the
team
and
indeed
it
reflects
well
on
our
new
genetic
variant
on
chromosome
instruments
cannot
facilitate
the
extraction
oral
delivery
of
a
powerful
drug
without
neurons,
involved
in of
Nearly
2.5
million
peopleofworldwide
are blindin
innovative
performance
Sigmoid
Pharma
of
study
lacks
colour
visionfor
and
inthose
daylight,
are
most
due
to diabetic
retinopathy.
secondary
aphotoreceptor
SFI codes
research
supplement,
highlights
the
SVUH
Education
& Research
Centre;
Dr.
partnership.
Athe
keyestablished,
driver
ofThis
successful
that
aused
protein,
known
asalleviate
Actlarge
quantities
of
data.
In
an
effort to
causing
systemic
side-effects.
colour
vision
and
used
in
daylight,
are
most
due
to
diabetic
retinopathy.
This
secondary
their
application
of
research
and
development.
comprehensive
and
centralised
data
affected
by
high glucose
complication
of
diabetes
activates
growth
potential
that
innovative
indigenous
Brian
Kirby
(dermatology)
andthe
Conway
scientific
research
in 2010
is meaningful
1,
which
isthe
thought
to
playlevels.
a key companies
role in
this
bottleneck
within
high-throughput
The
company
developed
two
new
drug
affected
by the
high glucose
levels.
complication
ofhas
diabetes
activates
theand
growth
collections,
and
information
of
new
leaky
blood
vessels
in
the eye
working
with
academia
canthe
realise.”
Under
normal
conditions,
gastrointestinal
Fellow,
Professor
Oliver
FitzGerald
interaction
ofstandards
academia
with
industry
thatis
both
humoral
and
cellular
immunity.
glycomic
projects,
the
NIBRT
team
have
The
research
team
made
their
observations
technologies,
LEDDS™
and
SmPill™,
which
of
new leaky
vessels
in
the eye
and is not
reporting
protocols
that
exist
within
responsible
forblood
the death
ofstudies
photoreceptors,
(rheumatology).
Both
have
The research
team made
their
developed
a web-based
tool
that
interfaces
using
a novel
zebrafish
model
ofobservations
diabetes,
Taylor’s
collaboration
with
Sigmoid
Pharma has
onlyneurons
enhance
the
solubility
permeability
responsible
for
the
death
ofand
photoreceptors,
genomics
and
proteomics.
the
that
send
visual
messages
to ourof
confirmed
known
genetic
associations
The
genetic
variant
identified
may
result
with
the
Waters
chromatography
software
using
a
novel
zebrafish
model
of
diabetes,
which
resembles
the
early
stages
of
diabetic
certainly
been
successful
by
these
metrics
with
the
drug
but
can
deliver
it
to
targeted
locations
the neurons
that associations
send visual messages
to our
brain.
but
additional
have
also
in
upregulation
of
the
IL-17
pathway,
a of
package
to
improve
and
automate
the
export
Researchers,
Dr
Natalia
Artemenko
and
Dr
which
resembles
the
early
stages
of
diabetic
retinopathy
in
humans.
It
is
an
exciting
three
co-authored
publications
to
date
in
two
in the identified.
gastrointestinal tract, including the
brain.
been
key
pro-inflammatory
which
Matthew
from the
National
Institute
of
data
to various
filescientific
formats
fornow
subsequent
retinopathy
inforhumans.
Itcytokine,
iswho
an
exciting
development
the
group
hope
to
Until
now,Campbell
it was unclear
if the
changes
to
the
highest
ranking
journals
in the
colon.
may
be
critical
in
explaining
of
Bioprocessing
Training
(NIBRT)
analysis.
The modular
architecture
of some
the
further
extend
their
andwhy
establish
ato
vessels
anditneurons
occurred
independently
field,
Gastroenterology
and Proceeding
oftool
the
development
for
theresearch
group
who
now
hope
Until
now,
was Research
unclear
if&the
changes
to of
Psoriatic
arthritis
(PsA)
is
an
people
with
psoriasis
develop
arthritis.
Theby
Sigmoid
Pharma-Taylor
collaboration
is
also
facilitates
the
manipulation
of establish
data as
from
led
Conway
Fellow,type
Professor
Pauline
Rudd
model
ofextend
late stage
disease.
one
other
andneurons
which
of retinal
neuron
is of
National
Academy
ofdiabetic
Sciences,
as
well
the
further
their
research
and
a
vessels
and
occurred
independently
inflammatory
joint
disease
that
is
This
important
observation
opens
up
facilitating
the which
development
of
a web-based
newneuron is
other
data
management
systems.
have
developed
an open
access,
generation
of proprietary
innovative
products
model
of
late
stage
diabetic
disease.
one
other
and
type
of
retinal
distinct
from
other for
chronic
arthritic
new
avenues
andjobs.
potential
therapeutic
approach
the treatment
of
interface
that
facilitates
extraction,
querying
and the
creationofofresearch
high-skilled
The
NIBRT
team arehave
now shown
working
to non
integrate
inflammatory
disease
(IBD)generated
byled
bringing
Meta-analysis
by UCD
researchers
by in
studies
in humans
that
and
sharing of bowel
HPLC-glycan
data
GlycoExtractor
with
the EUROCarbDB
More
than 15,000
people
in Ireland
and
together
the research
methodology
of the has
Conway
Fellow,
Professor
Denis Shields
progression
was
associated
with gross
high
throughput
processes.
framework
provide
a comprehensive
high-the
millions of to
people
worldwide
are living with
Taylor group with the proprietary
collaborator
scoops
Irish Timesvalidation
Innovationresearch
Award
Conway Conway
researcher
recognised
for biomarker
GlycoExtractor: A web-based interface for high
Reference
of HPLC-Glycan
throughput processing
GlycoExtractor:
A web-based
interface fordata
high
Natalia V. Artemenko,
Matthew
P. Campbell,
processing of
HPLC-Glycan
data and Pauline
throughput
tract
isV.lined
with
cells
block the
contents
subcellular
Thethat
applicability
of
IHCNatalia
Artemenko,
Matthew
P.Research,
Campbell,
and
Pauline
M. Rudd
Journallevel.
of Proteome
2010,
9 (4),
pp
of
the
into
the intestine.
In pp
an
MARK
infrom
oncology
has
been
demonstrated
M.
Ruddgut
Journal
ofleaking
Proteome
Research,
2010, 9 (4),
2037–2041
2037–2041
IBD
patient,
this barrier
is broken
and thetypes,
across
multiple
marker
and tumour
contents
of the
gut leak
out into surrounding
including
breast,
colorectal,
bladder and
areas.
The
research
team
in UCD Conway used
ovarian cancer.
a model of IBD and, by applying a new class of
drugs known as hydroxylase inhibitors, were
Dr. to
Rexhepaj
is now employed
by UCD
able
almost completely
reverse the
spin-out of
company
OncoMark Limited
symptoms
the disease.
of
HIV nef
critical
in determining
the the
rate
where
he are
hopes
to further
progress
of
disease
progression.
Professor
Denis
“When
we applied
these
new
drugs
to
our IBD
commercialisation
aspects
of IHC-MARK
Shieldsthe
believes
that
searches
modifiers
model,
gut was
tricked
into for
thinking
that itof
and complementary
image
analysis
progression
ratesprocesses
should
now
focusactivated
on
other
was
being
deprived
of oxygen.
This
models
to identify
involved
in early
approaches
in
histopathology.
hostprogression
and viral
factors.
“Systematic
evaluation
protective
pathways,
in turn
prevented
CKD
and which
investigate
novel
of large
ofthat
data
byslowing
bioinformatics
the
deathquantities
of
cells
line
the
strategies
forthe
preventing
and
the
can be just of
as the
important
inThese
refuting
gastrointestinal
tract,”
explained
Professor
progression
disease.
studies will
hypotheses
that
current
inepidemiological
the
literature,
Taylor.
“Our pre-clinical
trial
data
can
now
NIBRT
researchers
Matthew
Campbell
and
DrNatalia
Nataliaas
NIBRT
researchers
DrDrare
Matthew
Campbell
and
Dr
be
integrated
with
clinical
and
it is in the
discovering
unknown
patterns”,
he said.
Artemenko
who
developed
GlycoExtractor
inform
next
phase
Sigmoid
Pharma
product
Artemenko
who
developed
GlycoExtractor
studies
across
the
consortium
using
systems
development
pipeline”. in order to develop new
biology
methodologies
This research
was funded through Science
diagnostic
strategies
andUniversity
treatment
optionsinto
Foundation
Ireland
and
College
In addition to the product
that is currently
for
novel
therapeutic
strategies. tract
is lined
with cells that
block the contents
prevent
development.
Email
Dublin.
phase
IICKD
clinical
studies, Sigmoid
Pharma is
of the gut from leaking into
the intestine.
In an
[email protected]
for details
of a PhD
developing a LEDDS™-enabled
formulation
of
IBD
this
barrier
is broken and
the
Thepatient,
second
study
investigated
genetic
position
currently
available.
the hydroxylase
inhibitor
contents
the increase
gut leak out
into surrounding
variantsofthat
susceptibility
dimethyloxaloylglycine (DMOG) to bring about
areas.
The research
team in
UCD Conwayatused
to psoriasis
and found
associations
effective,
safe
and
targeted
delivery
of this
Reference:
onand,
theunreported
research,
DrDr
eight
genomic
aCommenting
modelpreviously
of IBD
by
applying
aKennedy
new
class of
Commenting
research,
Kennedy
potential
therapeutic
Meta-analysis
to on
test the
the agent.
association
of HIV-1
nef amino
loci.
Seven
loci
harboured
genes
with
drugs
known
as
hydroxylase
inhibitors,
were
said,
“By
establishing
a
robust
model
for
early
said,differences
“By establishing
a robust
model
for
early
acid
and deletions
with disease
progression.
recognised
functions
(IL28RA,
able
to almost
completely
reverse
the
and
late
stageimmune
diabetic
retinopathy,
weC.would
Ravindra
Pushker,
Jean-Marc
Jacquē,
Denis
Shields.
and late stage diabetic retinopathy, we would
REL,
IFIH1,
TRAF3IP2,
NFKBIA of
symptoms
ofERAP1,
the
disease.
Journal
ofbetter
Virology,
Apr
2010
p3644-3653
hope
to
understand
the progression
hopeTYK2).
to better
understand
theimplicate
progression of
and
These
findings
the
disease and
pave
the way
for identifying
EUROCarbDB,
a
research
infrastructure
design
“When
we applied
these
drugs
to our
IBD
the disease
and integrate
pave
thenew
way
for identifying
pathways
that
epidermal
new
drug
targets
fortricked
its 6th
successful
treatment”.
study
funded
bywas
the
EU
Framework
model,
the
gut
into
thinking
new
drug
targets
for
its
successful
treatment”.
barrier dysfunction with innate and that it
Programme.
Prospective
users
canScience
access
was
being deprived
ofdysregulation
oxygen.
This
activated
The
research
was funded
through
adaptive
immune
in thethe
GlycoExtractor
tool funded
onwhichthrough
The research
was
Science
protective
pathways,
incondition.
turn Research
prevented
pathogenesis
of this
skin
Foundation
Ireland
and
the Health
http://glycobase.nibrt.ie:8080/DemoGlycoExtra
the
death of the
cellsand
thatthe
lineHealth
the Research
Foundation
Ireland
Board.
ctor/mainPage.
gastrointestinal
tract,” explained Professor
Board.
Reference
Taylor.
pre-clinical
trial
can now
Reference
Common“Our
variants
at TRAF3IP2
aredata
associated
with
web-based
interface
for
high product
GlycoExtractor:
susceptibility
toApsoriatic
andPharma
psoriasis.
inform
the next
phasearthritis
Sigmoid
Reference:
processing
of
HPLC-Glycan
data
throughput
Hüffmeier
et al.
Nat Genet. 2010
Nov;42(11):996-9.
Reference:U cone
development
pipeline”.
Predominant
photoreceptor
dysfunction
in a
Bioinformatic analysis of HIV progression studies
Success in EU FP7 call
Conway
collaborator
scoopsand
Irishpsoriatic
Times Innovation
New genetic
insights
to psoriasis
arthritis Award
Zebrafish
Zebrafish model
model gives
gives insights
insights into
into diabetic
diabetic blindness
blindness
GlycoExtractor advances glycan data manipulation
V. Artemenko, Matthew P. Campbell, and Pauline
Natalia
PMID: 20953186
hyperglycaemic
model
of non-proliferative
diabetic
Predominant cone
photoreceptor
dysfunction
in a
M. addition
Rudd Journal
of Proteome
Research,
2010, 9 (4),inpp
In
to the
product
that is
currently
retinopathy.
Yolanda
Alvarez,
Jenneth
Chen,
Alison
hyperglycaemic
model
of non-proliferative
diabetic
2037–2041
phase
II clinical
studies,
Sigmoid
Pharma
Aretinopathy.
genome-wide
association
study
identifies
new is
Reynolds,
Nore
Waghorne,
John
J.
O’Connor,
Breandan
Yolanda Alvarez, Jenneth Chen,
Alison
psoriasis
susceptibility
loci
and
an
interaction
between
developing
a
LEDDS™-enabled
formulation
of
Kennedy.
Disease
Models
&
Mechanisms
(2010)
Reynolds, Nore Waghorne, John J. O’Connor, Breandan
HLA-C
andDisease
ERAP1. Models
Strange
et al Nat Genet.
2010 Oct
the
hydroxylase
inhibitor
Kennedy.
&AMechanisms
(2010)
17. PMID: 20953190
dimethyloxaloylglycine
(DMOG) to bring about
of HIV nef
areand
critical
in determining
effective,
safe
targeted
delivery ofthe
thisrate
of disease
progression.
Professor Denis
potential
therapeutic
agent.
Bioinformatic analysis of HIV progression studies